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Synthesis and biological evaluation of truncated
α-tubulin-binding pironetin analogues lacking alkyl
pendants in the side chain or the dihydropyrone ring†
Julián Paños,a Santiago Díaz-Oltra,a María Sánchez-Peris,a Jorge García-Pla,a
Juan Murga,*a Eva Falomir,a Miguel Carda,a Mariano Redondo-Horcajo,b
J. Fernando Díaz,*b Isabel Barasoain*b and J. Alberto Marco*c
The preparation of several new truncated analogues of the natural dihydropyrone pironetin is described.
They diﬀer from the natural product mainly in the suppression of some of the alkyl pendants in either
the side chain or the dihydropyrone ring. Their cytotoxic activity and their interactions with tubulin have
been investigated. It has been found that all analogues are cytotoxic towards two either sensitive or
resistant tumoral cell lines with similar IC50 values in each case, thus strongly suggesting that, like natural
pironetin, they also display a covalent mechanism of action. Their cytotoxicity is, however, lower than that
of the parent compound. This indicates that all alkyl pendants are necessary for the full biological activity,
with the ethyl group at C-4 seemingly being particularly relevant. Most likely, the alkyl groups cause a
restriction in the conformational mobility of the molecule and reduce the number of available con-
formations. This makes it more probable that the molecule preferentially adopts a shape which ﬁts better
into the binding point in α-tubulin.
Introduction
Microtubules are dynamic polymers which play a central role
in a number of cellular processes, particularly cell division, as
they are key constituents of the mitotic spindle.1 Their shape
can be described as hollow tubes of about 25 nm external dia-
meter composed of a protein named tubulin. The functional
form of this protein is a heterodimer formed in turn through
the non-covalent binding of two monomeric constituents.
These are two very similar polypeptides of about 450 amino
acid residues, called α- and β-tubulin.2 For cell division to
occur in a normal way, microtubules must be in a constant
state of formation and disruption, a process named micro-
tubule dynamics in which GTP hydrolysis into GDP plays a key
role.3
It is easy to understand that any molecule which exerts
some type of action on microtubule dynamics will be able to
influence the cell division process not only of normal cells but
also of tumoral ones. Since such an influence may be exerted
by molecules that bind to any of the tubulin components, it is
not surprising that tubulin-binding molecules (TBM) consti-
tute a most important class of anticancer agents.4 TBM are
able to interfere with microtubule assembly and functions,
either by causing disruption of the microtubules or through
their stabilization. In both cases, this results in mitotic arrest
of eukaryotic cells and subsequent cell death. Most of the
hitherto described active drugs are natural products or deriva-
tives thereof.5 Major drugs can already be found on the market
and many other promising compounds are in clinical trials.4,5
TBM may be divided into two broad categories: those that
bind to α-tubulin and those that bind to β-tubulin. The latter
group is presently by far the most numerous and contains pro-
ducts which cause either disruption or stabilization of micro-
tubules. Among the drugs that belong to this group, the
venerable alkaloid colchicine6 exerts its eﬀects by causing dis-
ruption of microtubules. In contrast, another renowned repre-
sentative of the same group, paclitaxel, was the first-described
tubulin-interacting drug that was found to stabilize micro-
tubules.7 In spite of the fact that they exert opposite eﬀects on
the mitotic spindle, both drugs are known to bind to
β-tubulin, even though to diﬀerent sites within this protein.
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The mechanisms of action8 of many of these TBM and the
molecular aspects9 of their interactions with tubulin have been
studied using a broad palette of methods.10
The number of products that bind to α-tubulin is very
small,11 the naturally occurring 5,6-dihydro-α-pyrone pironetin
(Fig. 1) being the first-reported example, followed a short time
later by the peptide-like hemiasterlin family.12 Pironetin is a
potent inhibitor of tubulin assembly and has been found to
arrest cell cycle progression in the G2/M phase.13 This feature
has motivated a number of groups to undertake total syntheses
of this natural compound.14 Some synthetic and biological
studies on modified variants of pironetin have recently been
published.15
Some structure–activity (SAR) studies on pironetin have
been reported.13 These studies have shown that the presence
of the conjugated C2vC3 double bond and of the hydroxyl
group at C-9, either free or methylated, is essential for the bio-
logical activity. The presence of a (7R)-hydroxyl group also
seems to be relevant.13 The epoxidation of the C12vC13
double bond has been shown to cause a decrease in the
activity13a,b but this may perhaps represent a negative feature of
the oxirane ring, rather than a strict need of this CvC bond. No
data are available about the importance of the remaining
structural features.15 It has been proposed that the Lys352
residue of the α-tubulin chain adds in a Michael fashion to the
conjugated double bond of pironetin, therefore forming a
covalent bond with C-3 of the dihydropyrone ring (Fig. 2). In
addition, it has been suggested that the Asn258 residue of
α-tubulin holds the pironetin molecule through two hydrogen
bonds to the dihydropyrone carbonyl and the methoxyl oxygen
atoms.13
The appearance of resistances to existing drugs has led to a
continuous need for developing new bioactive compounds that
overcome such problems. Even though first observed in the
case of antibiotics, resistances have also been reported to
TBM.4c,e,h,16 The investigation of new members of this com-
pound class therefore constitutes an important goal in chemi-
stry and pharmacology. As a member of the up to now small
group of products that bind to α-tubulin, pironetin constitutes
a pharmacologically interesting target. Thus, a key aim of our
research is the preparation of pironetin analogues that retain a
substantial proportion of the biological activity of the natural
metabolite while displaying a more simplified structure.
Although pironetin is not an extremely complex molecule, a
total synthesis will be lengthy enough to make preparation on
a large scale diﬃcult. Our investigation aims at establishing
which elements of the pironetin molecule are essential for its
activity and, if possible, at achieving an improvement of this
activity.
In order to develop SAR studies based upon the pironetin
framework, we designed two years ago17 a simplified model
structure where all elements that had not yet proven to be
essential for the biological activity were removed. The target
structures I/II are schematically shown in Fig. 3. The elements
that were maintained are the conjugated dihydropyrone ring
and the side chain with the methoxy group at C-9. The
hydroxyl group at C-7 was removed in some substrates (I) and
retained in others (II), in order to see its influence on the
activity. All alkyl pendants (methyl groups at C-8 and C-10,
Fig. 1 Structures of two natural products reported to selectively bind to
α-tubulin.
Fig. 2 Schematic model of the covalent union of pironetin to its binding site at
the α-tubulin surface.
Fig. 3 General structures of simpliﬁed pironetin analogues of the ﬁrst gene-
ration (ref. 17).
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ethyl at C-4) and the isolated C12vC13 double bond were
removed. The configurations of the two/three remaining
stereocentres were then varied in a systematic way. Thus, all
four possible stereoisomers with the general constitution I,
with no hydroxyl group at C-7, were prepared. Likewise, all
eight stereoisomers exhibiting the general structure II, with a
hydroxyl group at C-7, were synthesized.17
The cytotoxic activity of these analogues and their inter-
actions with tubulin were subsequently investigated. For the
measurement of the cytotoxic activity, the ovarian carcinoma
cell types A2780 (sensitive to chemotherapy) and A2780AD
(resistant to chemotherapy) were used. It was found on the one
hand that analogues I/II were cytotoxic in the low micromolar
range, thus much less active than the parent molecule.17 On
the other hand, we also found that they behaved in the same
way as pironetin in that they killed both sensitive and resistant
cells with similar IC50 values. This indicates that these com-
pounds are not substrates for the P-glycoprotein18 that resist-
ant cells overexpress in order to pump out cytotoxic
compounds, a feature expected for compounds which act
through a covalent mechanism of action.19 The general con-
clusion was that the simplified pironetin analogues I/II share
the mechanism of action of the natural compound and
compete for the same binding site to α-tubulin, leading to dis-
ruption of the microtubule network. Furthermore, it is worth
mentioning that variations in the configurations of the three
stereocentres (C-5, C-7, C-9) did not translate into significant
diﬀerences in the biological activity.17
In continuation of this line of research, we have now inves-
tigated the importance of the alkyl pendants in the pironetin
molecule for the biological properties of the natural com-
pound. In line with this reasoning, we have prepared the six
pironetin analogues 1–6 (Fig. 4). In all these compounds, the
configurations at the oxygenated carbons C-5, C-7 and C-9 are
as in natural pironetin. With respect to general structure II
(Fig. 3), compounds 1 and 2 contain an additional methyl
residue at C-10 with either configuration, whereas in com-
pounds 3 and 4, the extra methyl pendant is allocated at C-8.
Finally, compounds 5 and 6 display an extra alkyl residue
(methyl or ethyl) at C-4, in both cases with the same configur-
ation as in natural pironetin.
Results and discussion
Synthesis of compounds 1–6
The synthesis of dihydropyrones 1–6 followed in part the
general strategy based on iterative ozonolysis/allylation
sequences17 used for the preparation of I/II (Fig. 3). However,
the presence of the extra methyl or ethyl-bearing stereocentres
required the inclusion of additional elements in the strategy.
Scheme 1, for instance, depicts the synthesis of dihydropyrone
1. The chiral starting material was the commercially available
Roche ester 7, which was first converted into the known alde-
hyde 8 via a reported procedure.20 Asymmetric allylation of 8
by means of Brown’s methodology21 using the reagent combi-
nation (−)-Ipc2BCl/allylMgBr gave alcohol 9, which was then
methylated to 10 with methyl triflate and a bulky amine (2,6-
di-tert-butyl-4-methylpyridine).22 Desilylation of 10 followed by
tosylation of the alcohol function aﬀorded tosylate 12, which
was then coupled with a butylcuprate reagent23 to yield the
very volatile olefin 13. Ozonolysis of 13 gave the unstable alde-
hyde 14, which was not purified but immediately subjected in
crude form to asymmetric Brown allylation, this time using
(+)-Ipc2BCl/allylMgBr. Careful chromatographic purification of
the reaction product furnished alcohol 15 as a single stereo-
isomer in 66% overall yield from tosylate 12. After O-silylation
of 15, the ozonolysis/allylation sequence was repeated to give
homoallyl alcohol 17, which was then treated with acryloyl
chloride to yield ester 18. The latter was then subjected to
ring-closing metathesis24 with ruthenium first-generation cata-
lyst Ru-I to give 19, desilylation of which aﬀorded the target
molecule 1.
We then tried to prepare dihydropyrone 2 through the same
strategy used in the case of 1 but with the antipode of 7 as the
chiral starting compound. However, we met unanticipated pro-
blems with the olefin counterpart of 13 (Scheme 1). Its vola-
tility was much higher than that of its diastereoisomer, with
low yields in its preparation being the consequence. In view of
this, we took recourse to a diﬀerent strategy, depicted in
Scheme 2, where chirality was generated with the aid of an
asymmetric aldol reaction.
The syn relationship of the substituents at C-10 and C-9 in
dihydropyrone 2 led us to select the Evans aldol methodology25
for the preparation of this fragment of the molecule. Thus, the
Z boron enolate generated from the commercially available
N-propionyl oxazolidinone 20 was allowed to react with the
known chiral aldehyde 21.26 This yielded aldol adduct 22 with
good yield as well as excellent diastereoselectivity. Methylation
of 22 with trimethyloxonium tetrafluoroborate and Proton
Sponge® as a base22b furnished compound 23, the stereostruc-
ture of which was confirmed by means of an X-ray diﬀraction
analysis (see ESI†). Reductive cleavage of the chiral auxiliary
with LiBH4 was followed by tosylation of the primary alcohol
and coupling of the tosylate as above with the butylcuprateFig. 4 Structures 1–6 of the new series of pironetin analogues.
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reagent to yield olefin 26. The ozonolysis of 26 followed by
asymmetric allylation of the intermediate aldehyde (not
depicted in Scheme 2) gave alcohol 27, which was then sub-
jected to esterification to acrylate 28. Ruthenium-catalyzed
ring-closing metathesis of 28 furnished 29, which was sub-
sequently desilylated to the desired 2.
The anti relationship of the substituents at C-9 and C-8 in
dihydropyrone 3 led us to select the acetal variant27 of the
Crimmins aldol methodology28 for the preparation of this frag-
ment of the molecule. Thus, hexanal dimethylacetal29
(Scheme 3) was allowed to react with the titanium enolate of
N-propionyl thiazolidinethione 3030 to yield adduct 31 with
good diastereoselectivity (d.r. 90 : 10). Reductive cleavage of the
chiral auxiliary gave the intermediate aldehyde 32, which was
used in crude form in the asymmetric Brown allylation to yield
homoallyl alcohol 33, subsequently silylated to 34. As in the
previously discussed syntheses, an ozonolysis/asymmetric allyl-
ation sequence was performed on 34 to furnish alcohol 35,
which was esterified to acrylate 36. Ruthenium-catalyzed ring-
closing metathesis of 36 furnished 37, which was then desilyl-
ated to the target molecule 3.
In compound 4, the syn relationship of the substituents at
C-9 and C-8 led us to consider again an aldol reaction with a
chiral auxiliary of the Crimmins type. However, while the aldol
reaction worked in a satisfactory way, we were unable to
perform the O-methylation of the resulting aldol. We then
decided to switch to a chiral auxiliary of the Evans type. Thus,
the known Evans aldol adduct 3831 was methylated to yield 39
(Scheme 4). Reductive cleavage of the chiral auxiliary aﬀorded
the primary alcohol 40, which was then oxidized with the
Scheme 1 Synthesis of dihydropyrone 1. Abbreviations: DMAP, 4-(N,N-dimethylamino)pyridine; Ipc, isopinocampheyl; TBAF, tetra-n-butylammonium ﬂuoride; TBS,
tert-butyldimethylsilyl; TPS, tert-butyldiphenylsilyl; Tf, triﬂuoromethanesulfonyl; Ts, p-toluenesulfonyl; PPTS, pyridinium p-toluenesulfonate; Cy, cyclohexyl; 2,6-lut,
2,6-lutidine; DIPEA, ethyl N,N-diisopropylamine.
Scheme 2 Synthesis of dihydropyrone 2. Abbreviation: Bn, benzyl.
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Swern procedure32 to the corresponding aldehyde (not
depicted in Scheme 4). The latter was subjected to asymmetric
Brown allylation to give homoallyl alcohol 41, which was then
silylated to 42. Ozonolysis of 42 followed by asymmetric allyla-
tion of the intermediate aldehyde (not depicted in Scheme 4)
proceeded with good yield but medium diastereoselectivity
(d.r. 65 : 35). The major stereoisomer 43 was esterified to acrylate
44. Ruthenium-catalyzed ring-closing metathesis of 44 furn-
ished 45, which was then desilylated to the target molecule 4.
For the synthesis of dihydropyrones 5 and 6 we made again
use of Crimmins aldol methodology.28 The reaction sequence
was essentially identical for both compounds (Scheme 5).
Thus, the titanium enolate of N-propionyl thiazolidinethione
4633 was allowed to react with the known17 chiral aldehyde 48
to give adduct 49 with good diastereoselectivity. Silylation of
the hydroxy group in 49 to yield 50 followed by reductive clea-
vage of the chiral auxiliary provided aldehyde 53. Olefination
of 53 was performed using the Still–Gennari methodology34
and yielded conjugated ester 55 with good overall yield and
acceptable Z/E diastereoselectivity. Heating Z-55 in acidic
methanol at reflux caused cleavage of the two silyl groups but
not lactone ring closure. Forcing the reaction conditions led to
intramolecular Michael addition of one hydroxyl group to the
conjugated olefinic bond. However, isolation of the desilylated
product 57 followed by acidic treatment in benzene at room
temperature gave the desired 5.
Dihydropyrone 6 was obtained through an analogous reac-
tion sequence starting from N-butyryl thiazolidinethione 47.35
Biological properties of pironetin analogues
Cellular eﬀects of the compounds. We have determined the
IC50 values for pironetin analogues 1–6, as well as for synthetic
intermediates (E)-57, (Z)-57 and (Z)-58, and compared these
values with that of pironetin on both A2780 and A2780AD
human ovary carcinoma cells (Table 1). While pironetin was
active at the nanomolar range, the activities of the pironetin
analogues here under study were in the micromolar range,
that is, they are around three orders of magnitude less active.
The most cytotoxic compounds against both A2780 and multi-
resistant A2780AD cells were, in this order, 6, 1 and (E)-57 and,
to a somewhat lesser extent, 3 and (Z)-58. Compounds 4, 2 and
(Z)-57 were clearly less active, whereas 5 did not display a
noticeable activity. As shown in Table 1, pironetin and most of
the investigated compounds are able to overcome the resist-
ance of the A2780AD cell line due to eﬄux mediated by the
P-glycoprotein18 and show comparable IC50 values for the
resistant and parental cell lines. As already commented, this is
Scheme 3 Synthesis of dihydropyrone 3. Abbreviation: DIBAL, diisobutylaluminum hydride.
Scheme 4 Synthesis of dihydropyrone 4. Abbreviation: DMSO, dimethylsulfoxide.
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a feature expected for compounds which act through a covalent
mechanism of action.19
In order to study the eﬀect of the aforementioned pironetin
analogues on the microtubule cytoskeleton, we incubated cells
in the presence of these ligands for 24 hours (Fig. 5). Pironetin
at 50 nM concentration completely depleted cytoplasmic
microtubules (B and inset): cells are arrested in the prometa-
phase13a,b and type IV mitotic spindles are observed,36 with
the chromosomes being arranged in a ball of condensed DNA
with no microtubules. When using 50 μM 1, a reduction in the
number of microtubules and the presence of type III mitotic
spindles were observed, with a ball of condensed DNA enclos-
ing one or more star shaped aggregates of microtubules being
present in the preparations. Shrinking of the nucleus occurred
in some cells (C and inset). With higher concentrations of this
ligand (100 μM and 200 μM), a great cytotoxic eﬀect, extensive
cell death and nucleus shrinking was observed (results not
depicted in Fig. 5).
Ligands 3 and 4 at 100 μM concentration induced some
depolymerization of cytoplasmic microtubules and type III
mitotic spindles (D, E and insets). The most cytotoxic of all
tested ligands, compound 6 (25 μM) induced extensive micro-
tubule depletion and type IV mitotic spindles (F and inset).
Compound (E)-57, the second most cytotoxic ligand, at 50 μM
concentration induced microtubule depletion and both type
III and IV mitotic spindles (G and inset). Finally, ligand (Z)-58
(100 μM) induces microtubule depolymerization and type III
mitotic spindles (H and inset). In the presence of ligands 2, 5
and (Z)-57 at 100 μM (results not depicted in Fig. 5), the array
of microtubules looked like in control cells (A).
We next studied whether the aforementioned ligands were
capable of blocking cells in the G2/M phase of the cell cycle of
A549, as other microtubule inhibitors do. We incubated these
cells for 20 hours in the presence of the diﬀerent ligands or
the drug vehicle (Fig. 6 and Table 2). Pironetin at 50 nM con-
centration almost completely arrested cells in the G2/M phase
and, interestingly, so did 6 although at the micromolar level
(25 μM). Ligand (E)-57 (25 μM) also caused arrest at the G2/M
but to a somewhat lower level than 6. Ligands 1 (50 μM), and
(Z)-58 (100 μM) caused arrest to a much lower level whereas
ligands 2–5 and (Z)-57, all 100 μM, left the cell cycle practically
unaltered as compared with the control. Table 2 shows the per-
centage of cells in each phase of the cell cycle at the indicated
ligand concentration. As commented above, pironetin (50 nM),
6 (25 μM) and (E)-57 (25 μM) show the strongest eﬀects with
97%, 86% and 70%, respectively, of the cells being in the
G2/M phase.
Tubulin assembly. The critical concentration of purified
tubulin required for assembly was determined in GAB in the
presence of a large excess (100 μM) of dihydropyrones 1–6 and
synthetic intermediates (E)-57, (Z)-57 and (Z)-58 (Table 3). Doc-
etaxel is included in the Table as it is known to be a micro-
tubule-stabilizer agent, as shown by its low CrC value, and acts
therefore as a contrasting (positive) control element. As shown
in the Table, the concentration of tubulin required to produce
Scheme 5 Synthesis of dihydropyrones 5 and 6. Abbreviations: NMP, N-methylpyrrolidone; KHMDS, potassium hexamethyldisilazide.
Table 1 Eﬀects of pironetin analogues and synthetic intermediates on the
growth of A2780 and A2780AD (MDR overexpressing P-glycoprotein) ovarian
carcinoma cells
Compound IC50
a (A2780) IC50
a (A2780AD) R/Sb
Pironetin 0.009 ± 0.002 0.008 ± 0.001 0.8
1 25 ± 2 23 ± 1 0.9
2 51 ± 1 45 ± 3 0.9
3 32 ± 6 34 ± 1 1.1
4 43 ± 2 37 ± 4 0.9
5 >200 >200 —
6 10 ± 2 16 ± 1 1.6
(E)-57 18 ± 3 18.4 ± 1 1
(Z)-57 85 ± 12 188 ± 107 2.2
(Z)-58 32 ± 8 42 ± 6 1.3
a IC50 values (μM) are the mean ± standard error of three independent
experiments. bResistance index (relative resistance, obtained dividing
the IC50 of the resistant cell line by that of the parental A2780 cell
line).
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Fig. 5 Eﬀect of pironetin analogues 1, 3, 4, 6, (E)-57 and (Z)-58 as compared to the parental molecule pironetin on the microtubule network and nucleus mor-
phology. A549 cells were incubated for 24 hours with either drug vehicle DMSO (A), 50 nM pironetin (B), 50 μM 1 (C), 100 μM 3 (D), 100 μM 4 (E), 25 μM 6 (F),
50 μM (E)-57 (G) and 100 μM (Z)-58 (H). Microtubules are stained with α-tubulin antibodies, whereas DNA was stained with Hoechst 33342. Insets (A–H) are mitotic
spindles from the same preparation. The scale bar in H represents 10 μm. All panels have the same magniﬁcation.
Fig. 6 Cell cycle histograms of A549 lung carcinoma cells untreated or treated with pironetin analogues 1–6 and synthetic intermediates (E)-57, (Z)-57 and (Z)-58.
The lowest ligand concentration that induces maximal arrest in the G2/M phase is depicted.
Table 2 Cell cycle distribution of A549 cells treated with compounds 1–6, (E)-
57, (Z)-57 and (Z)-58a
Ligand Sub G1 G0/G1 S G2/M
Control 3 83 7 7
Pironetin 0.5 1 1.5 97
1 2 33 17 48
2 7 77 6 10
3 3 71 15 11
4 2 71 14 13
5 5 70 11 14
6 2 9 3 86
(E)-57 2 22 6 70
(Z)-57 4 78 7 11
(Z)-58 1 46 4 36
a Cells were incubated for 20 hours with the respective ligand at the
concentration indicated in Fig. 6. Numbers in the table are
percentages (%) of cells in each phase of the cell cycle. The sub-G1
peaks are presumably apoptotic cells.
Table 3 Critical concentration values of tubulin for microtubule assembly
induced by pironetin analogues 1–6 and intermediates (E)-57, (Z)-57 and (Z)-58
(ligand concentrations used are 25 μM for docetaxel and 100 μM for the
remaining compounds)
Compound CrCa (μM)
DMSO 3.30
Docetaxel 0.58 ± 0.46
Pironetin >15
1 3.23 ± 0.90
2 3.98 ± 0.15
3 3.75 ± 0.49
4 4.48 ± 1.32
5 3.86 ± 0.21
6 4.04 ± 0.56
(E)-57 3.91 ± 0.70
(Z)-57 4.96 ± 0.54
(Z)-58 3.18 ± 0.42
a CrC values are the mean ± standard error of at least three
independent experiments.
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assembly (critical concentration37) oscillate between 3.3 μM in
the absence of ligands (DMSO) and 4.96 μM in the presence of
(Z)-57, the most active of these compounds as regards this
particular property. The observed increase of the critical
concentration required indicates that most compounds in
the Table are also able to inhibit the assembly of tubulin.
This is that expected for a pironetin-like structure and
has already been observed in previous pironetin analogues
prepared by us.17
The highest in vitro activities were shown, in this order, by
compounds (Z)-57, 4, 6, 2 and (E)-57, followed by the remain-
ing ligands. It is noteworthy that molecules without the dihy-
dropyrone ring such as (Z)-57 and (E)-57 still retain a
significant percentage of this microtubule-destabilizing
activity. This likely suggests that the long side chain is still
able to interact with the pironetin binding site, even in the
absence of the dihydropyrone ring. However, since ligand 6
has been shown to be much more cytotoxic than (Z)-57, 4, 2
and (E)-57, it appears that the in vitro eﬀect expressed in
Table 2 does not correlate well with cellular results such as the
IC50 values (Table 1) or the cell cycle (Fig. 6), which are deter-
mined in vivo. This may possibly indicate that the various
chemical modifications performed in the pironetin molecule
have a significant eﬀect in the transport of the compounds
through the cell membrane.
The diﬀerences in activity between the compounds dis-
cussed here are not easy to explain. Compound 2, which has
the same configuration in its stereocentres as natural pirone-
tin, displays a lower cytotoxicity than its C-10 epimer 1
(Table 1), as well as a much lower ability to arrest cells at the
G2/M phase (Table 2). In contrast, 2 shows a higher ability to
inhibit tubulin assembly (Table 3). Compounds 3 and 4, epi-
meric at C-8, behave in almost the same way except for the
ability to inhibit tubulin assembly, which is much higher in 4.
The most surprising case is that of compounds 5 and 6. A
mere replacement of an ethyl group at C-4 (as in 6) by a methyl
group (as in 5) gives rise to a tremendous decrease in cytotoxi-
city (Table 1) and in the ability to inhibit tubulin assembly.
This is specially surprising in view of the fact that the pirone-
tin analogue lacking the alkyl group at C-4 is also much more
cytotoxic than 5 even though less than 6.17 The comparatively
high cytotoxicity of dihydropyrone 6 and conjugated ester
(E)-57 are coherent with the fact that they are the compounds
which cause an eﬀect on the microtubule network more
similar to pironetin (Fig. 5) and also a complete or extensive
arrest of the cell cycle at the G2/M phase (Fig. 6 and Table 2).
Summary
Pironetin analogues 1–6 were synthesized with the aim at
exploring the influence of the alkyl pendants of the parent
molecule in its biological activity. Most compounds proved
cytotoxic in the low micromolar range against both non-resist-
ant and multidrug resistant P-glycoprotein overexpressing,
ovarian carcinoma cell lines, similar IC50 values being found
in both cell lines. Thus, most of the aforementioned com-
pounds are able to inhibit microtubule assembly, both in vitro
and in cell cultures, therefore sharing the same general mech-
anism of action of tubulin assembly inhibition by the natural
dihydropyrone pironetin.
The results described above suggest that all alkyl pendants
are necessary for the full biological activity, perhaps with a
certain emphasis on the role of ethyl group at C-4. This is
most likely due to the fact that the alkyl groups restrict the
conformational mobility of the molecule and reduce the
number of available conformations.38,39 This further makes it
more probable that the molecule adopts a shape which fits
better into the binding point in α-tubulin. The preparation
and biological evaluation of further advanced pironetin ana-
logues, including those having hybrid structures, is currently
under way in our laboratory.
Experimental
Chemical procedures
NMR spectra were recorded at 500 MHz (1H NMR) and
125 MHz (13C NMR) in a CDCl3 solution at 25 °C, if not other-
wise indicated, with the solvent signals as the internal refer-
ence. 13C NMR signal multiplicities were determined with the
DEPT pulse sequence. Mass spectra were run in the electro-
spray (ESMS) mode. IR data, which were measured as films on
NaCl plates (oils) or as KBr pellets (solids), are given only when
relevant functions (CvO, OH) are present. Optical rotations
were measured at 25 °C. Reactions which required an inert
atmosphere (all except those involving water in the reaction
medium) were carried out under dry N2 with flame-dried glass-
ware. Commercial reagents were used as received. THF and
Et2O were freshly distilled from sodium-benzophenone ketyl.
Dichloromethane was freshly distilled from CaH2. Toluene was
freshly distilled from sodium wire. Tertiary amines were
freshly distilled from KOH. Unless detailed otherwise, “stan-
dard work-up” means pouring the reaction mixture into brine,
followed by extraction with the solvent indicated in paren-
theses. If the reaction medium was acidic, an additional washing
of the organic layer with 5% aq. NaHCO3 was performed. If the
reaction medium was basic, an additional washing with aq.
NH4Cl was performed. Where solutions were filtered through a
Celite pad, the pad was additionally washed with the same
solvent used, and the washings were incorporated into the
main organic layer. The latter was dried over anhydrous
Na2SO4 and the solvent was eliminated under reduced
pressure. Column chromatography of the residue on a silica
gel column (60–200 μm) was performed with elution with the
indicated solvent mixtures.
General reaction conditions. They are given below for reac-
tions which were repeated two or more times. Reactions that
are used only once are described together with the compound
they originate from. Compounds are described in numerically
increasing order.
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Asymmetric allylboration. Allylmagnesium bromide (com-
mercial 1 M solution in Et2O, 10 mL, 10 mmol) was added
dropwise under N2 via a syringe to a solution of (+)- or
(−)-Ipc2BCl (3.85 g, 12 mmol) in dry Et2O (50 mL) cooled in a
dry ice-acetone bath. After replacing the latter by an ice bath,
the mixture was stirred for 1 h. The solution was then allowed
to stand, which caused precipitation of magnesium chloride.
The supernatant solution was then carefully transferred to
another flask via canula. After cooling this flask at −78 °C, a
solution of the appropriate aldehyde (8 mmol) in dry Et2O
(25 mL) was added dropwise via a syringe. The resulting solu-
tion was further stirred at the same temp. for 1 h. The reaction
mixture was then quenched through the addition of a phos-
phate pH 7 buﬀer solution (50 mL), MeOH (50 mL) and 30%
H2O2 (25 mL). After stirring for 30 min, the mixture was
poured onto satd. aq. NaHCO3 and subjected to standard
work-up (Et2O). Column chromatography on silica gel
(hexanes–EtOAc mixtures) aﬀorded the desired homoallylic
alcohol. Compounds 9, 33 and 41 were prepared in this way
using in each case the appropriate enantiomer of Ipc2BCl
(yields and diastereomeric ratios are indicated in the corres-
ponding schemes).
Ozonolysis/asymmetric allylation sequence. The appropriate
olefin (10 mmol) was dissolved in dry CH2Cl2 (100 mL) and
cooled to −78 °C. A stream of ozone–oxygen was bubbled
through the solution until persistence of the bluish color. Dry
N2 was then bubbled through the solution for 10 min at the
same temperature. After addition of PPh3 (5.25 g, 20 mmol),
the solution was left to stir at room temperature for 2 h.
Solvent removal under reduced pressure gave a solid material,
which was stirred three times under pentane (3 × 25 mL). The
residual insoluble solid (Ph3PO) was discarded, and the
organic phase was evaporated under reduced pressure to yield
the crude aldehyde as a colorless oil, which was used as such
in the asymmetric allylation as described above (for weight cal-
culations, the yield of the ozonolysis step was assumed to be
quantitative). Compounds 15, 17, 27, 35 and 43 were prepared
in this way (yields and diastereomeric ratios are indicated in
the corresponding Schemes).
Silylation with TBSOTf. The appropriate alcohol (4 mmol)
was dissolved under N2 in dry CH2Cl2 (20 mL) and treated
sequentially with 2,6-lutidine (700 μL, 6 mmol) and TBSOTf
(1.15 mL, 5 mmol). The reaction mixture was then stirred for
1–2 h at room temperature until consumption of the starting
material (TLC monitoring). Standard work-up (CH2Cl2) and
column chromatography on silica gel (hexanes–EtOAc mix-
tures) aﬀorded the desired silylated derivative. Compounds 16,
34, 42, 50 and 52 were prepared in this way (yields are indi-
cated in the corresponding Schemes).
Acylation with acryloyl chloride. The appropriate alcohol
(5 mmol) was dissolved under N2 in dry CH2Cl2 (40 mL),
cooled to −78 °C and treated sequentially with ethyl N,N-diiso-
propylamine (2.6 mL, 15 mmol) and acryloyl chloride (810 μL,
10 mmol). The reaction mixture was then stirred for 2 h at
−78 °C. Standard work-up (CH2Cl2). Column chromatography
on silica gel (hexanes–EtOAc mixtures) aﬀorded the desired
ester. Compounds 18, 28, 36 and 44 were prepared in this way
(yields are indicated in the corresponding Schemes).
Ring-closing metathesis with ruthenium catalyst Ru-I. The
appropriate diolefin (1 mmol) was dissolved under N2 in dry,
degassed CH2Cl2 (100 mL) and treated with Grubbs first-gene-
ration ruthenium catalyst Ru-I (82 mg, 0.1 mmol). The mixture
was heated at reflux until consumption of the starting material
(2–3 h, TLC monitoring!). Solvent removal under reduced
pressure and column chromatography of the residue on silica
gel (hexanes–EtOAc mixtures) furnished the desired metathesis
product. Compounds 19, 29, 37 and 45 were prepared in this
way (yields are indicated in the corresponding Schemes).
Desilylation. (A) With PPTS/MeOH: the silylated compound
(0.6 mmol) was dissolved in MeOH (30 mL) and treated with
PPTS (30 mg, 0.12 mmol) and water (0.3 mL). The mixture was
then heated at reflux for 18 h, cooled and neutralized by
addition of solid NaHCO3. After filtering, the solution was
evaporated under reduced pressure, and the oily residue was
subjected to column chromatography on silica gel (hexanes–
EtOAc mixtures). This provided the desired hydroxy com-
pound. Compounds 1, (Z)-57, (E)-57 and 58 were prepared in
this way (yields are indicated in the corresponding Schemes).
(B) With aq. HF/MeCN: the silylated compound (0.1 mmol)
was dissolved in MeCN (4 mL) and treated with 48% HF
(36 μL, 1 mmol). The mixture was then stirred at room temp-
erature for 1.5 h. Standard work-up (EtOAc) and column
chromatography on silica gel (hexanes–EtOAc mixtures) furn-
ished the desired hydroxy compound. Compounds 2, 3 and 4
were prepared in this way (yields are indicated in the corres-
ponding Schemes).
Alcohol tosylation. A solution of the alcohol (10 mmol) in
CH2Cl2 (150 mL) was treated under N2 with DMAP (12 mg,
0.1 mmol), Et3N (7 mL, 50 mmol) and TsCl (5.72 g, 30 mmol).
The mixture was then stirred at room temperature for 18 h.
Standard work-up (CH2Cl2) and column chromatography on
silica gel (hexanes–EtOAc mixtures) aﬀorded the desired tosyl-
ate. Compounds 12 and 25 were prepared in this way (yields
are indicated in the corresponding Schemes).
Cross-coupling of a tosylate with lithium dibutylcuprate.
Copper(I) iodide (3.81 g, 20 mmol) was placed in a flask and
carefully desiccated by means of gentle heating under reduced
pressure. Then, it was suspended under N2 in dry Et2O
(40 mL), cooled to −35 °C and treated with nBuLi (commercial
1.6 M solution in hexane, 25 mL, 40 mmol). The mixture was
stirred at the same temperature for 30 minutes. The appropri-
ate tosylate (10 mmol) was dissolved in dry Et2O (50 mL) and
added dropwise under N2 to the cuprate solution, followed by
stirring for 1 h under the same conditions. Standard work-up
(Et2O) and column chromatography on silica gel (hexanes–
Et2O mixtures) provided the desired coupling product. Com-
pounds 13 and 26 were prepared in this way (yields are indi-
cated in the corresponding Schemes).
Caution: In the case of 13, evaporations have to be per-
formed under a not too low pressure in order to avoid losses
due to its marked volatility. Therefore, crude 13 contains vari-
able amounts of solvent and was used as such in the next step
Organic & Biomolecular Chemistry Paper
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(a small sample was purified for analytical purposes).
For this reason, the yield given in Scheme 1 refers to the
overall conversion of 12 into 15 (via 13 and the similarly vola-
tile aldehyde 14, for which the same caution has to be
observed).
Alcohol methylation. (A) With methyl triflate:22 a solution of
the alcohol (10 mmol) in dry CH2Cl2 (150 mL) was treated
under N2 at room temperature with 2,6-di-tert-butyl-4-methyl-
piridine (6.16 g, 30 mmol) and MeOTf (3.4 mL, 30 mmol). The
mixture was then stirred at reflux until consumption of the
starting material (12–18 h, TLC monitoring). Standard work-up
(extraction with CH2Cl2) and column chromatography on silica
gel (hexanes–EtOAc, 19 : 1) gave the desired O-methyl deriva-
tive. Compound 10 was prepared in this way in 88% yield. (B)
With Meerwein salt:22b a solution of the alcohol (2 mmol) in
dry CH2Cl2 (10 mL) was treated under N2 at room temperature
first with a solution of Proton Sponge® (2.14 g, 10 mmol) in
dry CH2Cl2 (8 mL) and then with a solution of trimethyloxo-
nium tetrafluoroborate (1.48 g, 10 mmol) in dry CH2Cl2
(8 mL). The reaction mixture was protected from light and
stirred at room temperature for 48 h. Standard work-up
(CH2Cl2) and column chromatography on silica gel (hexanes–
EtOAc mixtures) gave the desired O-methyl derivative. Com-
pounds 23 and 39 were prepared in this way (yields are indi-
cated in the corresponding Schemes).
Hydride reductions. (A) With LiBH4:
22b a solution of the
compound to be reduced (2 mmol) in dry Et2O (10 mL) was
cooled to −10 °C and treated with EtOH (140 μL, 2.4 mmol)
and then with LiBH4 (commercial 2 M solution in THF,
1.2 mL, 2.4 mmol). The reaction mixture was stirred at the
same temperature for 1 h. Standard work-up (Et2O) and
column chromatography on silica gel (hexanes–EtOAc mix-
tures) gave the desired product (a primary alcohol). Com-
pounds 24 and 40 were prepared in this way (yields are
indicated in the corresponding Schemes). (B) With DIBAL: a
solution of the compound to be reduced (2 mmol) in dry
CH2Cl2 (20 mL) was cooled to −78 °C and treated with DIBAL
(commercial 1 M solution in hexane, 4 mL, 4 mmol). The reac-
tion mixture was stirred at the same temperature for 30 min.
Standard work-up (CH2Cl2) and column chromatography on
silica gel (hexanes–EtOAc mixtures) gave the desired product
(an aldehyde). Compounds 32, 53 and 54 were prepared in this
way (yields are indicated in the corresponding Schemes).
(6S)-6-[(2R,4S,5R)-2-Hydroxy-4-methoxy-5-methyldecyl]-5,6-
dihydro-2H-pyran-2-one (1). Oil, [α]D −70.4 (c 0.7; CHCl3); IR
νmax (cm
−1): 3450 (br, OH), 1716 (CvO); 1H NMR δ 6.88 (1H,
ddd, J = 10, 5.8, 2.8 Hz), 6.01 (1H, br dd, J = 10, 1.5 Hz), 4.73
(1H, m), 4.20 (1H, tt, J = 9, 3 Hz), 3.34 (3H, s), 3.30 (1H, ddd, J
= 8, 5.6, 3 Hz), 3.00 (1H, br s, OH), 2.45–2.30 (2H, m),
1.90–1.80 (2H, m), 1.71 (1H, ddd, J = 14, 9.8, 3.5 Hz), 1.61 (1H,
ddd, J = 14.5, 8.3, 3 Hz), 1.54 (1H, ddd, J = 14.5, 8.3, 3 Hz),
1.35–1.10 (8H, br m), 0.88 (3H, t, J = 6.8 Hz), 0.82 (3H, d, J =
6.8 Hz); 13C NMR δ 164.4 (C), 145.2, 121.4, 82.6, 75.3, 65.1,
33.9 (CH), 42.8, 35.5, 33.1, 32.1, 30.0, 27.1, 22.6 (CH2), 56.7,
14.0, 13.9 (CH3); HR ESMS m/z 321.2040 (M + Na
+), calcd for
C17H30NaO4, 321.2042.
(6S)-6-[(2R,4S,5S)-2-Hydroxy-4-methoxy-5-methyldecyl]-5,6-
dihydro-2H-pyran-2-one (2). Oil, [α]D −34.2 (c 0.65; CHCl3); IR
νmax (cm
−1): 3450 (br, OH), 1712 (CvO); 1H NMR δ 6.88 (1H,
ddd, J = 10, 5, 3.5 Hz), 6.02 (1H, ddd, J = 10, 2.5, 1.5 Hz), 4.73
(1H, m), 4.20 (1H, m), 3.37 (3H, s), 3.30 (1H, ddd, J = 8, 5.3, 3.5
Hz), 3.00 (1H, br s, OH), 2.38 (2H, m), 1.90 (1H, ddd, J = 14,
8.8, 3 Hz), 1.80 (1H, m), 1.75–1.40 (5H, br m), 1.35–1.25 (6H,
br m), 0.89 (3H, t, J = 6.8 Hz), 0.88 (3H, d, J = 7 Hz); 13C NMR δ
164.3 (C), 145.2, 121.4, 83.3, 75.3, 65.3, 42.7 (CH), 36.3, 34.5,
32.2, 31.2, 30.1, 27.1, 22.6 (CH2), 57.3, 15.8, 14.1 (CH3); HR
ESMS m/z 321.2038 (M + Na+), calcd for C17H30NaO4, 321.2042.
(6S)-6-[(2R,3S,4R)-2-Hydroxy-4-methoxy-3-methylnonyl]-5,6-
dihydro-2H-pyran-2-one (3). Oil, [α]D −74 (c 0.24; CHCl3); IR
νmax (cm
−1): 3480 (br, OH), 1717 (CvO); 1H NMR δ 6.88 (1H,
ddd, J = 10, 6.3, 2.7 Hz), 6.02 (1H, ddd, J = 10, 2.5, 1 Hz), 4.70
(1H, m), 4.20 (1H, m), 3.45 (1H, br s, OH), 3.37 (3H, s), 3.22
(1H, br q, J ∼ 5.5 Hz), 2.44 (1H, dddd, J = 18.5, 6, 4.5, 1 Hz),
2.35 (1H, ddt, J = 18.5, 11.5, 2.5 Hz), 1.80–1.55 (5H, br m),
1.35–1.25 (6H, br m), 0.98 (3H, d, J = 7.4 Hz), 0.90 (3H, t, J =
6.8 Hz); 13C NMR δ 164.5 (C), 145.2, 121.4, 86.5, 75.7, 67.5,
39.9 (CH), 40.0, 32.0, 30.8, 30.3, 24.8, 22.6 (CH2), 58.0, 14.0,
12.1 (CH3); HR ESMS m/z 307.1882 (M + Na
+), calcd for
C16H28NaO4, 307.1885.
(6S)-6-[(2R,3R,4R)-2-Hydroxy-4-methoxy-3-methylnonyl]-5,6-
dihydro-2H-pyran-2-one (4). Oil, [α]D −75.1 (c 0.9; CHCl3); IR
νmax (cm
−1): 3460 (br, OH), 1719 (CvO); 1H NMR δ 6.88 (1H,
ddd, J = 10, 5.8, 2.8 Hz), 6.00 (1H, dt, J = 10, 1 Hz), 4.76 (1H,
m), 4.00 (1H, br s, OH), 3.94 (1H, td, J = 8, 2.5 Hz), 3.37 (3H, s),
3.29 (1H, m), 2.45–2.30 (2H, m), 1.96 (1H, br dd, J ∼ 14, 9 Hz),
1.82 (1H, m), 1.65–1.55 (2H, m), 1.50–1.40 (2H, m), 1.35–1.20
(5H, br m), 0.89 (3H, t, J = 6.8 Hz), 0.85 (3H, d, J = 7.3 Hz); 13C
NMR δ 164.5 (C), 145.2, 121.4, 85.6, 75.1, 70.0, 38.8 (CH), 41.4,
31.8, 30.3, 29.2, 26.1, 22.6 (CH2), 57.2, 14.0, 12.6 (CH3); HR
ESMS m/z 285.2067 (M + H+), calcd for C16H29O4, 285.2066.
(5R,6R)-6-[(2S,4R)-2-Hydroxy-4-methoxynonyl]-5-methyl-5,6-
dihydro-2H-pyran-2-one (5). A solution of ester Z-57 (32 mg,
0.1 mmol) and p-toluenesulfonic acid (3 mg, ca. 0.02 mmol) in
3 mL of dry benzene was stirred at room temperature until
consumption of the starting material (2–3 h, TLC monitoring).
Solvent removal under reduced pressure was performed fol-
lowed by column chromatography of the residue on silica gel
(hexanes–EtOAc, 1 : 1) to yield 5 (13 mg, 91%): oil, [α]D −32.4
(c 1.3; CHCl3); IR νmax (cm
−1): 3440 (br, OH), 1713 (CvO); 1H
NMR δ 6.96 (1H, dd, J = 9.8, 6.5 Hz), 5.96 (1H, br d, J ∼ 9.8 Hz),
4.78 (1H, dt, J = 7, 3 Hz), 4.25 (1H, br t, J ∼ 8.5 Hz), 3.49 (1H,
m), 3.37 (3H, s), 2.39 (1H, m), 1.84 (1H, ddd, J = 14, 10, 2.7
Hz), 1.78 (1H, ddd, J = 14, 9.5, 3.5 Hz), 1.75–1.45 (5H, br m),
1.40–1.20 (6H, br m), 1.06 (3H, d, J = 6.8 Hz), 0.91 (3H, t, J =
6.8 Hz); 13C NMR δ 164.7 (C), 151.8, 120.0, 79.9, 76.9, 64.8,
32.8 (CH), 39.7, 39.2, 32.7, 31.9, 25.3, 22.7 (CH2), 56.6, 14.0,
11.5 (CH3); HR ESMS m/z 307.1885 (M + Na
+), calcd for
C16H28NaO4, 307.1885.
(5R,6R)-5-Ethyl-6-[(2S,4R)-2-hydroxy-4-methoxynonyl]-5,6-
dihydro-2H-pyran-2-one (6). Compound 6 was obtained from
ester Z-58 in 83% yield under the same conditions used to
prepare 5: oil, [α]D −196 (c 0.6; CHCl3); IR νmax (cm−1): 3450
Paper Organic & Biomolecular Chemistry
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(br, OH), 1717 (CvO); 1H NMR δ 7.00 (1H, dd, J = 9.8, 5.8 Hz),
6.02 (1H, dd, J = 9.8, 1 Hz), 4.78 (1H, dt, J = 10, 3 Hz), 4.22 (1H,
br t, J ∼ 4.5 Hz), 3.48 (1H, m), 3.36 (4H, s, overlapping a broad
OH signal), 2.27 (1H, m), 1.86 (1H, ddd, J = 14, 10.3, 2.5 Hz),
1.76 (1H, ddd, J = 14, 8.8, 3.5 Hz), 1.70–1.45 (6H, br m),
1.40–1.20 (6H, br m), 0.97 (3H, t, J = 7.5 Hz), 0.90 (3H, t, J = 7
Hz); 13C NMR δ 164.7 (C), 150.6, 120.8, 79.9, 77.2, 64.8, 39.0
(CH), 39.3, 39.2, 32.7, 31.9, 25.3, 22.6, 20.8 (CH2), 56.6, 14.0,
11.0 (CH3); HR ESMS m/z 321.2038 (M + Na
+), calcd for
C17H30NaO4, 321.2042.
(2R,3S)-1-(tert-Butyldiphenylsilyloxy)-2-methylhex-5-en-3-ol
(9). Oil: [α]D −9.1 (c 1.3; CHCl3); IR νmax 3450 (br, OH) (cm−1);
1H NMR δ 7.70 (4H, m), 7.45–7.40 (6H, br m), 5.94 (1H, ddt, J =
17, 10.3, 7), 5.15–5.10 (2H, m), 3.79 (1H, dd, J = 10.2, 4.5 Hz),
3.71 (1H, td, J = 7.5, 4 Hz), 3.66 (1H, dd, J = 10.2, 6.8 Hz), 3.40
(1H, br s, OH), 2.38 (1H, m), 2.25–2.20 (1H, m), 1.84 (1H, m),
1.08 (9H, s), 0.88 (3H, d, J = 7.3 Hz); 13C NMR δ 133.0 (×2), 19.2
(C), 135.7 (×2), 135.6 (×2), 135.3, 129.8 (×2), 127.7 (×4), 75.1, 39.6
(CH), 117.2, 68.5, 39.4 (CH2), 26.9 (×3), 13.4 (CH3); HR ESMS
m/z 391.2072 (M + Na+), calcd for C23H32NaO2Si, 391.2069.
tert-Butyl [(2R,3S)-3-methoxy-2-methylhex-5-enyloxy] diphe-
nylsilane (10). Oil, [α]D +6 (c 1.25; CHCl3);
1H NMR δ 7.70 (4H,
m), 7.45–7.40 (6H, br m), 5.87 (1H, ddt, J = 17, 10.3, 7),
5.15–5.05 (2H, m), 3.72 (1H, dd, J = 10, 6 Hz), 3.63 (1H, dd, J =
10, 5.5 Hz), 3.35 (1H, m), 3.33 (3H, s), 2.35–2.30 (1H, m),
2.20–2.15 (1H, m), 1.97 (1H, apparent heptuplet, J ∼ 6.2 Hz),
1.08 (9H, s), 0.94 (3H, d, J = 7 Hz); 13C NMR δ 134.0, 133.9,
19.4 (C), 135.7 (×2), 135.6 (×2), 135.4, 129.6, 129.5, 127.6 (×4),
81.6, 38.2 (CH), 116.5, 65.7, 34.3 (CH2), 57.3, 26.9 (×3), 12.7
(CH3); HR ESMS m/z 405.2229 (M + Na
+), calcd for
C24H34NaO2Si, 405.2226.
(2R,3S)-3-Methoxy-2-methylhex-5-en-1-ol (11). Compound 10
(7.65 g, 20 mmol) was dissolved in THF (250 mL) and treated
with TBAF trihydrate (7.57 g, 24 mmol). The mixture was
stirred for 24 h at room temperature. Standard work-up
(EtOAc) and column chromatography on silica gel (hexanes–
EtOAc, 4 : 1) gave alcohol 11 (2.25 g, 78%): oil, [α]D +51.9 (c 1.1;
CHCl3); IR νmax (cm
−1): 3400 (br, OH); 1H NMR (CD3OD) δ 5.75
(1H, ddt, J = 17, 10.3, 7), 5.10–5.00 (2H, m), 3.55 (1H, dd, J =
10.7, 6.3 Hz), 3.43 (1H, dd, J = 10.7, 5.5 Hz), 3.31 (3H, s), 3.18
(1H, td, J = 6.5, 4.5 Hz), 2.40–2.25 (1H, m), 2.20–2.10 (1H, m),
1.81 (1H, m), 0.88 (3H, d, J = 7 Hz) (OH signal not detected);
13C NMR (CD3OD) δ 136.2, 83.8, 39.5 (CH), 117.2, 65.2, 35.5
(CH2), 57.7, 13.3 (CH3); HR ESMS m/z 167.1045 (M + Na
+),
calcd for C8H16NaO2, 167.1048.
(2R,3S)-3-Methoxy-2-methylhex-5-enyl p-toluenesulfonate
(12). Oil, [α]D +28.8 (c 1.3; CHCl3);
1H NMR δ 7.80 (2H, br d,
J ∼ 8 Hz), 7.35 (2H, br d, J ∼ 8 Hz), 5.75 (1H, ddt, J = 17, 10.3, 7),
5.10–5.05 (2H, m), 4.05 (2H, m), 3.24 (3H, s), 3.10 (1H, m), 2.45
(3H, s), 2.32 (1H, m), 2.16 (1H, m), 1.94 (1H, m), 0.92 (3H, d,
J = 7 Hz); 13C NMR δ 144.6, 133.1 (C), 133.7, 129.7 (×2), 127.9
(×2), 80.7, 36.0 (CH), 117.4, 72.4, 34.2 (CH2), 57.3, 21.5,
13.2 (CH3); HR ESMS m/z 321.1140 (M + Na
+), calcd for
C15H22NaO4S, 321.1137.
(4S,5R)-4-Methoxy-5-methyldec-1-ene (13). Oil, [α]D +8.2
(c 1.5; CHCl3);
1H NMR δ 5.86 (1H, ddt, J = 17, 10.3, 7), 5.07 (1H.
br dd, J = 17, 1.5 Hz), 5.03 (1H, br dd, J = 10.3, 1 Hz), 3.34 (3H,
s), 3.03 (1H, dt, J = 7.2, 4.8 Hz), 2.25–2.15 (2H, m), 1.70 (1H,
m), 1.40–1.10 (8H, br m), 0.89 (3H, t, J = 7.2 Hz), 0.86 (3H, d,
J = 6.8 Hz); 13C NMR δ 136.0, 85.1, 35.2 (CH), 116.2, 34.4, 32.5,
32.2, 27.1, 22.7 (CH2), 57.3, 14.8, 14.1 (CH3); HR ESMS m/z
207.1733 (M + Na+), calcd for C12H24NaO, 207.1725.
(4R,6S,7R)-6-Methoxy-7-methyldodec-1-en-4-ol (15). Oil, [α]D
−24 (c 1; CHCl3); IR νmax (cm−1): 3425 (br, OH); 1H NMR δ 5.82
(1H, ddt, J = 17, 10.3, 7), 5.15–5.10 (2H, m), 3.90 (1H, m), 3.37
(3H, s), 3.35 (1H, m, overlapped), 2.50 (1H, br s, OH), 2.25 (2H,
br t, J ∼ 6.5 Hz), 1.85 (1H, m), 1.58 (1H, ddd, J = 14.5, 8.8, 2.5
Hz), 1.50 (1H, ddd, J = 14.5, 8.8, 2.5 Hz), 1.40–1.10 (8H, br m),
0.89 (3H, t, J = 7.2 Hz), 0.83 (3H, d, J = 6.8 Hz); 13C NMR δ
135.0, 82.3, 68.1, 34.2 (CH), 117.5, 42.3, 35.1, 33.1, 32.1, 27.1,
22.6 (CH2), 57.0, 14.0, 13.9 (CH3); HR ESMS m/z 251.1990 (M +
Na+), calcd for C14H28NaO2, 251.1987.
tert-Butyl [(4R,6S,7R)-6-methoxy-7-methyldodec-1-en-4-yloxy]
dimethylsilane (16). Oil, [α]D −61.8 (c 1; CHCl3); 1H NMR δ
5.82 (1H, ddt, J = 17, 10.3, 7), 5.05–5.00 (2H, m), 3.94 (1H, m),
3.30 (3H, s), 3.29 (1H, m, overlapped), 2.25 (2H, br t, J ∼ 6 Hz),
1.87 (1H, m), 1.45–1.10 (10H, br m), 0.91 (9H), 0.90 (3H, t, J =
6.8 Hz), 0.80 (3H, d, J = 6.8 Hz), 0.09 (6H, s); 13C NMR δ 18.1
(C), 134.9, 80.5, 68.7, 33.2 (CH), 116.9, 43.1, 36.6, 33.3, 32.2,
27.4, 22.6 (CH2), 56.1, 26.0 (×3), 14.1, 13.5, −4.0, −4.7 (CH3);
HR ESMS m/z 365.2862 (M + Na+), calcd for C20H42NaO2Si,
365.2852.
(4S,6R,8S,9R)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-9-
methyltetradec-1-en-4-ol (17). Oil, [α]D −28.6 (c 1.2; CHCl3); IR
νmax (cm
−1): 3450 (br, OH); 1H NMR δ 5.83 (1H, ddt, J = 17,
10.3, 7), 5.10–5.05 (2H, m), 4.16 (1H, apparent sextuplet, J ∼
4 Hz), 4.03 (1H, m), 3.27 (3H, s), 3.20 (1H, br dt, J ∼ 10, 2.5 Hz),
2.25–2.15 (2H, m), 1.88 (1H, m), 1.71 (1H, ddd, J = 14, 10.5,
4 Hz), 1.64 (1H, ddd, J = 14, 8.5, 1.5 Hz), 1.56 (1H, dt, J = 14, 2.7
Hz), 1.47 (1H, ddd, J = 14, 10.5, 3.7 Hz), 1.40–1.10 (9H, br m),
0.89 (12H, br s, overlapping a methyl triplet), 0.80 (3H, d, J =
6.8 Hz), 0.12 (3H, s), 0.09 (3H, s); 13C NMR δ 17.9 (C), 135.0,
80.8, 69.7, 68.1, 33.0 (CH), 117.0, 42.4, 42.3, 35.9, 33.2, 32.1,
27.4, 22.6 (CH2), 55.9, 25.9 (×3), 14.0, 13.2, −4.2, −4.9 (CH3);
HR ESMS m/z 409.3112 (M + Na+), calcd for C22H46NaO3Si,
409.3114.
(4S,6R,8S,9R)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-9-
methyltetradec-1-en-4-yl acrylate (18). Oil, [α]D −7.6 (c 0.8;
CHCl3); IR νmax (cm
−1): 1726 (CvO); 1H NMR δ 6.38 (1H, dd,
J = 17.5, 1.5 Hz), 6.10 (1H, dd, J = 17.5, 10.5 Hz), 5.80–5.70 (2H,
m), 5.10–5.00 (3H, m), 3.87 (1H, apparent quintuplet, J ∼ 6
Hz), 3.30 (3H, s), 3.21 (1H, br dt, J ∼ 8, 4 Hz), 2.45–2.35 (2H,
m), 1.90–1.80 (2H, m), 1.73 (1H, ddd, J = 14, 6.6, 4.5 Hz),
1.50–1.45 (2H, m), 1.40–1.10 (8H, br m), 0.89 (12H, br s, over-
lapping a methyl triplet), 0.83 (3H, d, J = 6.8 Hz), 0.06 (3H, s),
0.05 (3H, s); 13C NMR δ 165.6, 18.0 (C), 133.4, 129.0, 81.1, 71.2,
67.5, 33.6 (CH), 130.2, 117.9, 42.2, 39.0, 37.9, 33.0, 32.2, 27.4,
22.7 (CH2), 56.2, 26.0 (×3), 14.0, 13.7, −4.2, −4.3 (CH3); HR
ESMS m/z 463.3401 (M + H+), calcd for C25H49O4Si, 463.3400.
(6S)-6-[(2R,4S,5R)-2-(tert-Butyldimethylsilyloxy)-4-methoxy-5-
methyldecyl]-5,6-dihydro-2H-pyran-2-one (19). Oil, [α]D −40
(c 1; CHCl3); IR νmax (cm
−1): 1732 (CvO); 1H NMR δ 6.86 (1H,
Organic & Biomolecular Chemistry Paper
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ddd, J = 10, 5, 3.5 Hz), 6.00 (1H, br d, J ∼ 10 Hz), 4.56 (1H, m),
4.04 (1H, m), 3.27 (3H, s), 3.16 (1H, dt, J = 9, 3 Hz), 2.35–2.25
(2H, m), 2.06 (1H, ddd, J = 14, 9, 4 Hz), 1.82 (1H, m), 1.64 (1H,
ddd, J = 14, 9, 4 Hz), 1.50 (1H, ddd, J = 14, 6, 2.5 Hz), 1.44 (1H,
ddd, J = 14, 6, 4 Hz), 1.35–1.10 (8H, br m), 0.88 (3H, t, J = 6.8
Hz), 0.87 (9H, br s), 0.79 (3H, d, J = 6.8 Hz), 0.07 (3H, s), 0.05
(3H, s); 13C NMR δ 164.3, 18.0 (C), 145.1, 121.4, 81.3, 74.6,
66.8, 33.4 (CH), 43.6, 38.2, 33.1, 32.1, 30.0, 27.3, 22.6 (CH2),
56.1, 25.9 (×3), 14.1, 13.5, −4.4, −4.5 (CH3); HR ESMS m/z 435.
2907 (M + Na+), calcd for C23H44NaO4Si, 435.2907.
(4R)-4-Benzyl-3-[(2R,3S,5R)-5-(tert-butyldimethylsilyloxy)-3-
hydroxy-2-methyloct-7-enoyl]oxazolidin-2-one (22). A solution
of oxazolidinone 20 (1.17 g, 5 mmol) in CH2Cl2 (15 mL) was
treated under N2 with triethyl amine (1.4 mL, 10 mmol). The
mixture was cooled to 0 °C and treated with Bu2BOTf (commer-
cial 1 M solution in CH2Cl2, 7.5 mL, 7.5 mmol), followed by
stirring at 0 °C for 1 h and then at −78 °C for 30 min. After
this time, a solution of aldehyde 21 (3.42 g, 15 mmol) in
CH2Cl2 (15 mL) was added. The stirring was maintained for
2 h under the same conditions. The reaction was quenched by
addition of buﬀer pH 7 (30 mL) and MeOH (30 mL), followed
by 30% H2O2 (15 mL). After allowing the mixture to reach
room temperature, standard work-up (CH2Cl2) and column
chromatography on silica gel (hexanes–EtOAc, 9 : 1, then 4 : 1)
yielded compound 22 (1.91 g, 83%): oil, [α]D −89.6 (c 1.1;
CHCl3); IR νmax (cm
−1): 3530 (br, OH), 1781, 1702 (CvO); 1H
NMR δ 7.35–7.15 (5H, br m), 5.80 (1H, ddt, J = 17.3, 10.2,
7 Hz), 5.10–5.05 (2H, m), 4.70 (1H, m), 4.30–4.15 (3H, m), 4.05
(1H, m), 3.76 (1H, qd, J = 7, 3.8 Hz). 3.40 (1H, s, OH), 3.28 (1H,
m), 2.78 (1H, dd, J = 13, 9.5 Hz), 2.35–2.30 (2H, m), 1.70–1.65
(1H, m), 1.55–1.50 (1H, m), 1.25 (3H, d, J = 7 Hz), 0.88 (9H, s),
0.10 (3H, s), 0.08 (3H, s); 13C NMR δ 176.6, 153.1, 135.2, 18.0
(C), 134.5, 129.4 (×2), 128.9 (×2), 127.3, 70.0, 68.3, 55.2, 41.6
(CH), 117.4, 66.1, 43.0, 39.1, 37.7 (CH2), 25.8 (×3), 11.2, −4.5,
−4.8 (CH3); HR ESMS m/z 484.2492 (M + Na+). Calcd for
C25H39NNaO5Si, 484.2495.
(4R)-4-Benzyl-3-[(2R,3S,5R)-5-(tert-butyldimethylsilyloxy)-3-
methoxy-2-methyloct-7-enoyl]oxazolidin-2-one (23). Solid, mp
60–61 °C (slow evaporation from MeCN), [α]D −22.9 (c 0.7;
CHCl3); IR νmax (cm
−1): 1781, 1702 (CvO); 1H NMR δ
7.30–7.15 (5H, br m), 5.77 (1H, ddt, J = 17.3, 10.2, 7 Hz),
5.05–5.00 (2H, m), 4.59 (1H, m), 4.20 (1H, qd, J = 6.8, 5 Hz),
4.09 (2H, m), 3.85 (1H, m), 3.52 (1H, dt, J = 7.7, 4.5 Hz). 3.36
(3H, s), 3.25 (1H, br dd, J ∼ 13, 3 Hz), 2.74 (1H, dd, J = 13, 9.5
Hz), 2.22 (2H, br t, J ∼ 5.7 Hz), 1.58 (2H, m), 1.15 (3H, d, J =
7 Hz), 0.86 (9H, s), 0.06 (3H, s), 0.05 (3H, s); 13C NMR δ 175.0,
153.1, 135.3, 18.0 (C), 134.5, 129.4 (×2), 128.8 (×2), 127.2, 80.0,
68.7, 55.8, 39.5 (CH), 117.1, 65.9, 42.6, 39.0, 37.7 (CH2), 57.7,
25.9 (×3), 12.9, −3.9, −4.8 (CH3); HR ESMS m/z 476.2834
(M + H+). Calcd for C26H42NO5Si, 476.2832.
(2S,3S,5R)-5-(tert-Butyldimethylsilyloxy)-3-methoxy-2-methyl-
oct-7-en-1-ol (24). Oil, [α]D −39.5 (c 1.4; CHCl3); IR νmax
(cm−1): 3425 (br, OH); 1H NMR δ 5.82 (1H, ddt, J = 17, 10, 7
Hz), 5.10–5.00 (2H, m), 3.92 (1H, m), 3.68 (1H, dd, J = 10.8, 8.5
Hz), 3.51 (1H, dd, J = 10.8, 5 Hz), 3.45 (1H, dt, J = 9.2, 3 Hz),
3.40 (3H, s), 2.30–2.20 (3H, m), 2.70 (1H, br s, OH), 1.62 (1H,
ddd, J = 14, 9.2, 3.2 Hz), 1.51 (1H, ddd, J = 14, 8.8, 3 Hz), 0.90
(9H, s), 0.82 (3H, d, J = 7 Hz), 0.09 (3H, s), 0.08 (3H, s); 13C
NMR δ 18.1 (C), 134.5, 82.1, 68.8, 42.7 (CH), 117.2, 65.9, 36.8,
35.2 (CH2), 57.1, 25.9 (×3), 12.6, −3.9, −4.6 (CH3); HR ESMS
m/z 303.2358 (M + H+). Calcd for C16H35O3Si, 303.2355.
(2S,3S,5R)-5-(tert-Butyldimethylsilyloxy)-3-methoxy-2-methyl-
oct-7-enyl p-toluenesulfonate (25). Oil, [α]D −59.9 (c 1;
CHCl3); IR νmax (cm
−1): 1363, 1180 (SO2);
1H NMR δ 7.80 (2H,
br d, J ∼ 8 Hz), 7.32 (2H, br d, J ∼ 8 Hz), 5.79 (1H, ddt, J = 17,
10, 7 Hz), 5.05–5.00 (2H, m), 4.10 (1H, dd, J = 9.3, 6 Hz), 3.84
(2H, m), 3.33 (1H, m), 3.22 (3H, s), 2.43 (3H, s), 2.20 (2H, m),
2.15–2.10 (1H, m), 1.45–1.35 (2H, m), 0.86 (12H, s, overlapping
a methyl doublet), 0.06 (3H, s), 0.05 (3H, s); 13C NMR δ 144.6,
133.3, 18.0 (C), 134.3 (×2), 129.8, 127.8 (×2), 78.1, 71.9, 37.7
(CH), 117.2, 68.8, 42.4, 35.1 (CH2), 57.2, 25.9 (×3), 21.5, 11.8,
−4.0, −4.7 (CH3); HR ESMS m/z 479.2255 (M + H+). Calcd for
C23H40O5SSi, 479.2263.
tert-Butyl [(4R,6S,7S)-6-methoxy-7-methyldodec-1-en-4-yloxy]
dimethylsilane (26). Oil, [α]D −61.5 (c 1.1; CHCl3); 1H NMR δ
5.83 (1H, ddt, J = 17, 10, 7 Hz), 5.10–5.00 (2H, m), 3.91 (1H,
m), 3.32 (3H, s), 3.24 (1H, dt, J = 8.2, 3.6 Hz), 2.25–2.20 (2H,
m), 1.77 (1H, m), 1.50–1.20 (10H, br m), 0.91 (12H, s, overlap-
ping a methyl triplet), 0.83 (3H, d, J = 7 Hz), 0.08 (6H, s); 13C
NMR δ 18.1 (C), 134.8, 81.6, 69.0, 37.6 (CH), 116.9, 42.9, 34.2,
32.2, 30.9, 27.4, 22.7 (CH2), 56.7, 25.9 (×3), 15.5, 14.1, −4.0,
−4.6 (CH3); HR ESMS m/z 343.3025 (M + H+). Calcd for
C20H43O2Si, 343.3032.
(4S,6R,8S,9S)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-9-
methyltetradec-1-en-4-ol (27). Oil, [α]D −36.5 (c 0.95; CHCl3);
IR νmax (cm
−1): 3450 (br, OH); 1H NMR δ 5.84 (1H, ddt, J = 17,
10, 7 Hz), 5.15–5.05 (2H, m), 4.15 (1H, m), 4.05 (1H, m), 3.50
(1H, br s, OH), 3.31 (3H, s), 3.14 (1H, dt, J = 9, 3.3 Hz),
2.30–2.15 (2H, m), 1.80–1.20 (13H, br m), 0.91 (12H, s, overlap-
ping a methyl triplet), 0.85 (3H, d, J = 7 Hz), 0.13 (3H, s), 0.10
(3H, s); 13C NMR δ 17.9 (C), 135.1, 81.9, 69.8, 68.1, 33.8 (CH),
117.2, 42.4, 42.1, 36.7, 32.2, 30.7, 27.4, 22.7 (CH2), 56.5, 25.9
(×3), 15.5, 14.1, −4.3, −4.8 (CH3); HR ESMS m/z 387.3298 (M +
H+), calcd for C22H47O3Si, 387.3294.
(4S,6R,8S,9S)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-9-
methyltetradec-1-en-4-yl acrylate (28). Oil, [α]D −5.7 (c 0.9;
CHCl3); IR νmax (cm
−1): 1727 (CvO); 1H NMR δ 6.36 (1H, dd,
J = 17.3, 1.5 Hz), 6.10 (1H, dd, J = 17.3, 10.4 Hz), 5.85–5.70 (2H,
m), 5.10–5.05 (3H, m), 3.83 (1H, apparent quintuplet, J ∼ 6
Hz), 3.30 (3H, s), 3.15 (1H, br td, J ∼ 6.2, 3.5 Hz), 2.45–2.30
(2H, m), 1.83 (1H, ddd, J = 14, 8.4, 5 Hz), 1.75–1.65 (2H, m),
1.52 (2H, t, J = 6 Hz), 1.45–1.10 (8H, br m), 0.89 (12H, br s,
overlapping a 3H triplet), 0.83 (3H, d, J = 7 Hz), 0.05 (3H, s),
0.03 (3H, s); 13C NMR δ 165.5, 18.0 (C), 133.4, 129.0, 81.9, 71.2,
67.5, 34.4 (CH), 130.2, 117.9, 42.1, 39.0, 38.8, 32.2, 31.2, 27.4,
22.6 (CH2), 56.8, 25.9 (×3), 15.3, 14.1, −4.3, −4.4 (CH3); HR
ESMS m/z 463.3221 (M + Na+), calcd for C25H48NaO4Si, 463.3220.
(6S)-6-[(2R,4S,5S)-2-(tert-Butyldimethylsilyloxy)-4-methoxy-5-
methyldecyl]-5,6-dihydro-2H-pyran-2-one (29). Oil, [α]D −51.8
(c 1; CHCl3); IR νmax (cm
−1): 1732 (CvO); 1H NMR δ 6.88 (1H,
ddd, J = 10, 4.5, 3.5 Hz), 6.03 (1H, dt, J = 10, 3.5 Hz), 4.60 (1H,
m), 4.05 (1H, m), 3.32 (3H, s), 3.14 (1H, dt, J = 8, 3.5 Hz),
Paper Organic & Biomolecular Chemistry
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2.35–2.30 (2H, m), 2.05 (1H, ddd, J = 14, 9, 4 Hz), 1.80–1.40
(6H, br m), 1.35–1.20 (6H, br m), 0.89 (12H, br s, overlapping a
3H triplet), 0.85 (3H, d, J = 7 Hz), 0.10 (3H, s), 0.08 (3H, s); 13C
NMR δ 164.3, 18.0 (C), 145.2, 121.5, 82.3, 74.6, 66.8, 34.3 (CH),
43.5, 39.1, 32.2, 31.0, 30.0, 27.4, 22.6 (CH2), 56.8, 25.9 (×3),
15.4, 14.1, −4.3, −4.4 (CH3); HR ESMS m/z 435.2902 (M + Na+),
calcd for C23H44NaO4Si, 435.2907.
(2R,3R)-1-[(4S)-4-Isopropyl-2-thioxothiazolidin-3-yl]-3-methoxy-
2-methyloctan-1-one (31). A solution of N-propionyl thiazolidi-
nethione 30 (4.35 g, 20 mmol) in dry CH2Cl2 (175 mL) was
cooled under N2 to 0 °C and treated dropwise with TiCl4
(2.4 mL, 22 mmol). The mixture was then cooled to −78 °C fol-
lowed by dropwise addition of DIPEA (3.83 mL, 22 mmol). The
temperature of the mixture was then allowed to reach −40 °C,
followed by stirring for 2 h. Recooling to −78 °C was followed
by dropwise sequential addition of a solution of hexanal
dimethyl acetal (1.73 mL, 10 mmol) in dry CH2Cl2 (5 mL) and
then SnCl4 (1.17 mL, 10 mmol). Stirring was continued for
15 min at −78 °C and then for 4 h at −20 °C. Standard work-
up (CH2Cl2) and column chromatography on silica gel
(hexanes–EtOAc, 4 : 1) aﬀorded compound 31 (2.1 g, 63%)
obtained as a 90 : 10 mixture of diastereoisomers. For analyti-
cal purposes, a small sample of pure 31 could be prepared via
a careful column chromatography: oil, [α]D +174.2 (c 1.5;
CHCl3); IR νmax (cm
−1): 1697 (CvO); 1H NMR δ 5.28 (1H, m),
5.02 (1H, apparent quintuplet, J ∼ 7 Hz), 3.63 (1H, td, J = 8.2,
3.5 Hz), 3.44 (1H, dd, J = 11.5, 8.5 Hz), 3.30 (3H, s), 2.98 (1H,
dd, J = 11.5, 1.7 Hz), 2.30 (1H, m), 1.60–1.20 (8H, br m), 1.08
(3H, d, J = 6.8 Hz), 1.06 (3H, d, J = 7 Hz), 0.98 (3H, d, J = 7 Hz),
0.89 (3H, t, J = 7 Hz); 13C NMR δ 202.5, 177.1 (C), 82.5, 71.8,
42.0, 30.6 (CH), 32.1, 29.8, 29.1, 24.3, 22.6 (CH2), 57.5, 19.1,
17.1, 14.1, 13.2 (CH3); HR ESMS m/z 354.1541 (M + Na
+), calcd
for C16H29NNaO2S2, 354.1537.
(4R,5S,6R)-6-Methoxy-5-methylundec-1-en-4-ol (33). Pre-
pared from 31 (90 : 10 mixture of diastereoisomers) via 32 and
obtained also as a 90 : 10 diastereoisomeric mixture, which
was used as such in the next step: oil; IR νmax (cm
−1) 3470 (br,
OH); 1H NMR (signals from the major diastereoisomer) δ 5.80
(1H, ddt, J = 17, 10, 7 Hz), 5.10–5.00 (2H, m), 3.92 (1H, td, J =
6.8, 1.5 Hz), 3.38 (3H, s), 3.18 (1H, br q, J ∼ 5.5 Hz), 3.15 (1H,
br s, OH), 2.25 (1H, m), 2.12 (1H, m), 1.70–1.45 (4H, br m),
1.35–1.20 (6H, br m), 0.94 (3H, d, J = 7 Hz), 0.88 (3H, t, J = 6.8
Hz); 13C NMR (signals from the major diastereoisomer) δ
135.5, 85.6, 70.5, 39.0 (CH), 116.5, 38.7, 32.0, 30.6, 24.6, 22.5
(CH2), 57.8, 13.9, 10.8 (CH3); HR ESMS m/z 237.1835 (M +
Na+), calcd for C13H26NaO2, 237.1831.
tert-Butyl [(4R,5R,6R)-6-methoxy-5-methylundec-1-en-4-yl-
oxy] dimethylsilane (34). Oil, [α]D −25.4 (c 0.96; CHCl3); 1H
NMR δ 5.80 (1H, ddt, J = 17, 10, 7 Hz), 5.10–5.00 (2H, m), 3.97
(1H, td, J = 6.5, 3.3 Hz), 3.28 (3H, s), 3.16 (1H, m), 2.30–2.20
(2H, m), 1.80–1.70 (1H, m), 1.60–1.20 (8H, br m), 0.90 (12H, br
s, overlapping a 3H triplet), 0.80 (3H, d, J = 7 Hz), 0.07 (3H, s),
0.06 (3H, s); 13C NMR δ 18.2 (C), 135.1, 81.0, 71.3, 40.3 (CH),
116.7, 38.9, 32.3, 29.3, 23.9, 22.7 (CH2), 56.0, 26.0 (×3), 14.1,
9.0, −3.8, −4.7 (CH3); HR ESMS m/z 329.2876 (M + H+), calcd
for C19H41O2Si, 329.2876.
(4S,6R,7R,8R)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-7-
methyltridec-1-en-4-ol (35). Oil, [α]D +2.8 (c 1.5; CHCl3); IR
νmax (cm
−1): 3450 (br, OH); 1H NMR δ 5.83 (1H, ddt, J = 17,
10.2, 7 Hz), 5.20–5.10 (2H, m), 4.00–3.90 (2H, m), 3.31 (3H, s),
3.08 (1H, m), 3.00 (1H, br s, OH), 2.30–2.20 (2H, m), 2.00 (1H,
apparent sextuplet, J ∼ 6.5 Hz), 1.62 (2H, m), 1.45–1.20 (8H, br
m), 0.90 (15H, br s, overlapping a methyl triplet and a methyl
doublet), 0.12 (3H, s), 0.09 (3H, s); 13C NMR δ 18.1 (C), 134.8,
81.2, 72.1, 68.2, 42.4 (CH), 117.7, 40.7, 39.4, 32.1, 29.2, 24.6,
22.7 (CH2), 56.4, 26.0 (×3), 14.1, 10.4, −4.1, −4.6 (CH3); HR
ESMS m/z 395.2950 (M + Na+), calcd for C21H44NaO3Si,
395.2957.
(4S,6R,7R,8R)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-7-
methyltridec-1-en-4-yl acrylate (36). Oil, [α]D −7.8 (c 0.2;
CHCl3); IR νmax (cm
−1): 1727 (CvO); 1H NMR δ 6.38 (1H, dd,
J = 17, 1.5 Hz), 6.10 (1H, dd, J = 17, 10.4 Hz), 5.80–5.70 (2H, m),
5.15–5.05 (2H, m), 4.98 (1H, m), 4.06 (1H, br t, J ∼ 6.5 Hz), 3.26
(3H, s), 3.14 (1H, m), 2.40–2.30 (2H, m), 1.90–1.55 (4H, br m),
1.40–1.20 (7H, br m), 0.88 (12H, br s, overlapping a methyl
triplet), 0.80 (3H, d, J = 6.8 Hz), 0.05 (3H, s), 0.04 (3H, s); 13C
NMR δ 165.7, 18.2 (C), 133.4, 128.9, 80.7, 71.5, 68.6, 40.5 (CH),
130.3, 118.0, 39.3, 38.6, 32.3, 29.3, 23.4, 22.7 (CH2), 55.8, 26.0
(×3), 14.1, 9.0, −4.1, −4.5 (CH3); HR ESMS m/z 449.3067 (M +
Na+), calcd for C24H46NaO4Si, 449.3063.
(6S)-6-[(2R,3R,4R)-2-(tert-Butyldimethylsilyloxy)-4-methoxy-3-
methylnonyl]-5,6-dihydro-2H-pyran-2-one (37). Oil, [α]D −28.3
(c 0.7; CHCl3); IR νmax (cm
−1): 1732 (CvO); 1H NMR δ 6.88
(1H, m), 6.02 (1H, br d, J ∼ 9.8 Hz), 4.49 (1H, m), 4.22 (1H, m),
3.30 (3H, s), 3.17 (1H, m), 2.40–2.30 (2H, m), 1.97 (1H, ddd, J =
14, 8, 5.8 Hz), 1.73 (1H, ddd, J = 14, 7.5, 5 Hz), 1.65–1.50 (2H,
br m), 1.50–1.20 (7H, br m), 0.89 (12H, br s, overlapping a
methyl triplet), 0.82 (3H, d, J = 7.3 Hz), 0.09 (3H, s), 0.07 (3H,
s); 13C NMR δ 164.2, 18.2 (C), 145.0, 121.5, 80.7, 74.9, 67.8,
41.0 (CH), 40.9, 32.2, 29.8, 29.5, 23.6, 22.7 (CH2), 56.1, 26.0
(×3), 14.1, 9.7, −4.1, −4.3 (CH3); HR ESMS m/z 421.2753 (M +
Na+), calcd for C22H42NaO4Si, 421.2750.
(4S)-4-Benzyl-3-[(2S,3R)-3-methoxy-2-methyloctanoyl] oxazo-
lidin-2-one (39). Oil, [α]D +63.4 (c 0.56; CHCl3); IR νmax (cm
−1):
1782, 1698 (CvO); 1H NMR δ 7.35–7.20 (5H, br m), 4.62 (1H,
m), 4.20–4.10 (2H, m), 4.02 (1H, apparent quintuplet, J ∼ 6.5
Hz), 3.40 (1H, br q, J ∼ 6 Hz), 3.35 (3H, s), 3.27 (1H, br dd, J ∼
13.2, 3 Hz), 2.76 (1H, dd, J = 13.2, 9.8 Hz), 1.50–1.40 (3H, br
m), 1.35–1.25 (6H, br m), 1.23 (3H, d, J = 7 Hz), 0.87 (3H, t, J =
6.8 Hz); 13C NMR δ 175.2, 152.9, 135.2 (C), 129.2 (×2), 128.7
(×2), 127.1, 82.4, 55.5, 40.9 (CH), 65.8, 37.5, 31.7, 31.6, 25.2,
22.4 (CH2), 58.0, 13.8, 12.4 (CH3); HR ESMS m/z 348.2173 (M +
H+). Calcd for C20H30NO4, 348.2175.
(2R,3R)-3-Methoxy-2-methyloctan-1-ol (40). Oil: [α]D −6.6
(c 1.19; CHCl3); IR νmax (cm
−1): 3410 (br, OH); 1H NMR δ 3.66
(1H, dd, J = 10.6, 7.5 Hz), 3.55 (1H, dd, J = 10.7, 4.9 Hz), 3.37
(3H, s), 3.24 (1H, m), 2.60 (1H, br s, OH), 2.00 (1H, m),
1.54 (1H, m), 1.40 (2H, m), 1.35–1.25 (5H, br m), 0.89 (3H, t,
J = 7 Hz), 0.86 (3H, d, J = 7 Hz); 13C NMR δ 85.0. 36.6 (CH),
66.3, 32.0, 29.7, 25.9, 22.6 (CH2), 57.6, 14.0, 11.5 (CH3);
HR ESMS m/z 197.1519 (M + Na+), calcd for C10H22NaO2,
197.1517.
Organic & Biomolecular Chemistry Paper
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(4R,5R,6R)-6-Methoxy-5-methylundec-1-en-4-ol (41). A solu-
tion of DMSO (4.26 mL, 60 mmol) in dry CH2Cl2 (60 mL) was
cooled under N2 to −78 °C and treated with oxalyl chloride
(2.54 mL, 30 mmol). After stirring at the same temperature for
5 min, a solution of alcohol 40 (24 mmol) in CH2Cl2 (20 mL)
was added dropwise. The mixture was then stirred at −78 °C
for a further 15 min. After addition of triethyl amine (16.8 mL,
120 mmol), the mixture was stirred for 5 min at −78 °C and
then for 20 min at 0 °C. Standard work-up (CH2Cl2) aﬀorded
an aldehyde which was used in crude form in the subsequent
allylation step (see the conditions above) to yield 41: oil, [α]D
−2.6 (c 1.61; CHCl3); IR νmax (cm−1): 3470 (br, OH); 1H NMR δ
5.86 (1H, ddt, J = 17, 10.3, 7 Hz), 5.10–5.00 (2H, m), 3.70 (1H,
br s, OH), 3.62 (1H, td, J = 7.8, 4.5 Hz), 3.33 (3H, s), 3.30 (1H,
m), 2.30 (1H, m), 2.12 (1H, m), 1.78 (1H, qd, J = 7.3, 3 Hz), 1.55
(1H, m), 1.40–1.30 (2H, m), 1.30–1.20 (5H, br m), 0.85 (3H, t,
J = 6.8 Hz), 0.80 (3H, d, J = 7.3 Hz); 13C NMR δ 135.1, 84.4,
73.2, 38.0 (CH), 116.8, 39.8, 31.8, 29.5, 25.9, 22.5 (CH2), 57.2,
13.9, 11.9 (CH3); HR ESMS m/z 215.2013 (M + H
+), calcd for
C13H27O2, 215.2011.
tert-Butyl [(4R,5S,6R)-6-methoxy-5-methylundec-1-en-4-yloxy]
dimethylsilane (42). Oil, [α]D −26.9 (c 0.93; CHCl3); 1H NMR δ
5.88 (1H, ddt, J = 17, 10.3, 7 Hz), 5.05–5.00 (2H, m), 3.75 (1H,
br q, J ∼ 5.5 Hz), 3.33 (3H, s), 3.28 (1H, m), 2.30–2.20 (2H, m),
1.65 (1H, m), 1.55 (1H, m), 1.43 (1H, m), 1.35–1.20 (6H, br m),
0.91 (12H, br s, overlapping a 3H triplet), 0.85 (3H, d, J = 6.8
Hz), 0.07 (3H, s), 0.06 (3H, s); 13C NMR δ 18.2 (C), 135.4, 81.1,
73.2, 41.6 (CH), 116.5, 38.0, 32.1, 30.8, 25.4, 22.7 (CH2), 57.2,
26.0 (×3), 14.1, 9.0, −4.0, −4.6 (CH3); HR ESMS m/z 329.2872
(M + H+), calcd for C19H41O2Si, 329.2876.
(4S,6R,7S,8R)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-7-
methyltridec-1-en-4-ol (43). Major stereoisomer formed in the
ozonolysis/allylation of 42 (for configurational assignment, see
ESI†): oil, [α]D −1.6 (c 0.36; CHCl3); IR νmax (cm−1): 3480 (br,
OH); 1H NMR δ 5.83 (1H, ddt, J = 17, 10.2, 7 Hz), 5.15–5.05
(2H, m), 4.03 (1H, td, J = 6.6, 3 Hz), 3.95 (1H, m), 3.31 (3H, s),
3.22 (1H, dt, J = 7.5, 4.5 Hz), 2.90 (1H, br s, OH), 2.22 (2H, m),
1.84 (1H, m), 1.70–1.40 (4H, br m), 1.35–1.20 (6H, br m),
0.91 (12H, br s, overlapping a 3H triplet), 0.85 (3H, d, J =
6.8 Hz), 0.13 (3H, s), 0.10 (3H, s); 13C NMR δ 18.0 (C), 135.0,
81.0, 72.0, 67.9, 42.6 (CH), 117.4, 41.3, 38.2, 32.1, 30.2,
25.2, 22.7 (CH2), 56.7, 25.9 (×3), 14.0, 9.0, −4.2, −4.8 (CH3);
HR ESMS m/z 373.3139 (M + H+), calcd for C21H45O3Si,
373.3138.
(4S,6R,7S,8R)-6-(tert-Butyldimethylsilyloxy)-8-methoxy-7-
methyltridec-1-en-4-yl acrylate (44). Oil, [α]D +32 (c 0.61;
CHCl3); IR νmax (cm
−1): 1726 (CvO); 1H NMR δ 6.36 (1H, br d,
J ∼ 17 Hz), 6.09 (1H, dd, J = 17, 10.3 Hz), 5.80–5.70 (2H, m),
5.10–5.00 (3H, m), 3.76 (1H, m), 3.32 (3H, s), 2.92 (1H, br q,
J ∼ 5.5 Hz), 2.40 (2H, br t, J ∼ 6.3 Hz), 1.78 (1H, m), 1.62 (2H,
m), 1.51 (1H, m), 1.43 (1H, m), 1.35–1.20 (6H, br m), 0.92 (3H,
d, J = 6.8 Hz), 0.88 (12H, br s, overlapping a 3H triplet), 0.01
(3H, s), 0.00 (3H, s); 13C NMR δ 165.6, 18.0 (C), 133.4, 129.0,
83.1, 71.6, 70.2, 42.5 (CH), 130.1, 117.8, 39.3, 36.3, 32.2, 30.5,
24.3, 22.7 (CH2), 57.4, 25.9 (×3), 14.0, 8.7, −4.3, −4.9 (CH3); HR
ESMS m/z 427.3248 (M + H+), calcd for C24H47O4Si, 427.3244.
(6S)-6-[(2R,3S,4R)-2-(tert-Butyldimethylsilyloxy)-4-methoxy-3-
methylnonyl]-5,6-dihydro-2H-pyran-2-one (45). Oil, [α]D −4.2 (c
0.45; CHCl3); IR νmax (cm
−1): 1730 (CvO); 1H NMR δ 6.87 (1H,
dt, J = 9.7, 4.5 Hz), 6.00 (1H, d, J = 9.7 Hz), 4.56 (1H, m), 4.06
(1H, br d, J ∼ 9 Hz), 3.28 (3H, s), 2.96 (1H, br q, J ∼ 5.5 Hz),
2.30 (2H, m), 1.80 (2H, m), 1.60–1.40 (3H, br m), 1.35–1.20
(6H, br m), 0.86 (3H, d, J = 6.8 Hz), 0.84 (12H, br s, overlapping
a 3H triplet), 0.05 (3H, s), 0.03 (3H, s); 13C NMR δ 164.3, 18.0
(C), 145.3, 121.4, 82.7, 74.7, 69.9, 42.3 (CH), 37.5, 31.9, 30.7,
30.2, 24.9, 22.6 (CH2), 57.1, 25.8 (×3), 14.0, 7.4, −4.5, −4.8
(CH3); HR ESMS m/z 399.2930 (M + H
+), calcd for C22H43O4Si,
399.2931.
(2S,3R,5R,7R)-1-[(4S)-4-Benzyl-2-thioxothiazolidin-3-yl]-5-
(tert-butyldimethylsilyloxy)-3-hydroxy-7-methoxy-2-methyldo-
decan-1-one (49). A solution of thiazolidinethione 46 (1.6 g,
6 mmol) in dry CH2Cl2 (60 mL) was cooled under N2 to −78 °C
and treated dropwise with TiCl4 (690 μL, 6.3 mmol). After stir-
ring for 15 min, the mixture was treated dropwise with DIPEA
(1.15 mL, 6.6 mmol). The stirring was then kept for a further
45 min. Addition of N-methylpyrrolidone (1.16 mL, 12 mmol)
was followed by stirring for 15 min, addition of a solution of
aldehyde 48 (2.09 g, 6.6 mmol) in dry CH2Cl2 (25 mL) and
further stirring for 1 h at −30 °C. Standard work-up (CH2Cl2)
and column chromatography on silica gel (hexanes–EtOAc,
9 : 1) aﬀorded aldol adduct 49 (2.41 g, 69%) as an
88 : 12 mixture of diastereoisomers. These could then be separ-
ated with a second careful chromatography on silica gel
(hexanes–EtOAc, 19 : 1). Data are given for the major diastereo-
isomer: oil, [α]D +88.6 (c 1.3; CHCl3); IR νmax (cm
−1): 3470 (br,
OH), 1697 (CvO); 1H NMR δ 7.30–7.20 (5H, br m), 5.24 (1H,
m), 4.53 (1H, m), 4.30 (1H, m), 4.15 (1H, m), 3.65 (1H, s, OH),
3.35 (1H, dd, J = 11.2, 6.8 Hz), 3.29 (3H, s), 3.30–3.20 (2H, m),
3.03 (1H, dd, J = 13.2, 10.7 Hz), 2.85 (1H, d, J = 11.7 Hz), 1.80
(1H, m), 1.70 (2H, m), 1.55–1.40 (3H, br m), 1.35–1.20 (6H, br
m), 1.23 (3H, d, J = 6.3 Hz), 0.88 (12H, br s, overlapping a 3H
triplet), 0.11 (3H, s), 0.08 (3H, s); 13C NMR δ 201.2, 177.1,
136.6, 17.9 (C), 129.4 (×2), 128.9 (×2), 127.1, 77.2, 69.9, 69.3,
69.0, 44.4 (CH), 40.8, 39.7, 36.7, 32.7, 32.1, 32.0, 24.2,
22.6 (CH2), 55.6, 25.8 (×3), 14.0, 11.1, −4.4, −4.9 (CH3); HR
ESMS m/z 604.2926 (M + Na+), calcd for C30H51NNaO4S2Si,
604.2926.
(2S,3R,5S,7R)-1-[(4S)-4-Benzyl-2-thioxothiazolidin-3-yl]-3,5-
bis(tert-butyldimethylsilyloxy)-7-methoxy-2-methyldodecan-1-
one (50). Oil, [α]D +99.1 (c 1.15; CHCl3); IR νmax (cm
−1): 1702
(CvO); 1H NMR δ 7.30–7.20 (5H, br m), 5.20 (1H, m), 4.55 (1H,
m), 4.02 (1H, apparent q, J ∼ 5.5 Hz), 3.83 (1H, apparent quin-
tuplet, J ∼ 6.2 Hz), 3.27 (3H, overlapped m), 3.25 (3H, s), 3.00
(1H, dd, J = 12.7, 10.7 Hz), 2.83 (1H, d, J = 11.3 Hz), 1.80 (1H,
m), 1.70–1.65 (2H, m), 1.50–1.40 (3H, m), 1.35–1.20 (6H, br m),
1.20 (3H, d, J = 6.4 Hz), 0.88 (12H, br s, overlapping a 3H
triplet), 0.86 (9H, s), 0.08 (3H, s), 0.07 (6H, s), 0.03 (3H, s); 13C
NMR δ 200.8, 176.5, 136.8, 18.1, 18.0 (C), 129.5 (×2), 128.9 (×2),
127.2, 77.5, 72.1, 69.5, 67.4, 45.1 (CH), 44.7, 43.0, 36.5, 33.2,
32.2, 32.0, 24.5, 22.7 (CH2), 56.0, 26.0 (×3), 25.9 (×3), 14.1, 13.1,
−3.5, −3.6, −4.1, −4.4 (CH3); HR ESMS m/z 718.3798 (M +
Na+), calcd for C36H65NNaO4S2Si2, 718.3791.
Paper Organic & Biomolecular Chemistry
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(2S,3R,5R,7R)-1-[(4S)-4-Benzyl-2-thioxothiazolidin-3-yl]-5-
(tert-butyldimethylsilyloxy)-2-ethyl-3-hydroxy-7-methoxydode-
can-1-one (51). Obtained in 65% yield as a single diastereo-
isomer through reaction of thiazolidinethione 47 with aldehyde
48 under the same conditions as for the preparation of 49: Oil,
[α]D +77.5 (c 1.15; CHCl3); IR νmax (cm
−1): 1697 (CvO); 1H
NMR δ 7.35–7.25 (5H, br m), 5.32 (1H, m), 4.89 (1H, dt, J = 8.8,
5 Hz), 4.31 (1H, br dd, J ∼ 9.3, 5 Hz), 4.20 (1H, apparent sextu-
plet, J ∼ 4 Hz), 3.70 (1H, br s, OH), 3.34 (1H, br dd, J ∼ 11.3, 7
Hz), 3.31 (3H, s), 3.30–3.25 (2H, m), 3.08 (1H, dd, J = 13, 10.6
Hz), 2.85 (1H, d, J = 11.2 Hz), 2.00–1.85 (2H, m), 1.75–1.60 (3H,
br m), 1.60–1.40 (3H, br m), 1.40–1.25 (6H, br m), 1.00 (3H, t,
J = 7.5 Hz), 0.88 (12H, s, overlapping one methyl triplet), 0.12
(3H, s), 0.10 (3H, s); 13C NMR δ 201.7, 176.1, 136.7, 17.9 (C),
129.5 (×2), 128.9 (×2), 127.2, 77.2, 70.0, 69.4, 69.3, 50.3 (CH),
40.7, 39.1, 37.0, 32.7, 32.1, 32.0, 24.3, 22.7, 20.4 (CH2), 55.6,
25.9 (×3), 14.1, 11.8, −4.4, −4.8 (CH3); HR ESMS m/z 618.3087
(M + Na+), calcd for C31H53NNaO4S2Si, 618.3083.
(2S,3R,5S,7R)-1-[(4S)-4-Benzyl-2-thioxothiazolidin-3-yl]-3,5-
bis(tert-butyldimethylsilyloxy)-2-ethyl-7-methoxydodecan-1-one
(52). Oil, [α]D +47.3 (c 1.5; CHCl3); IR νmax (cm
−1): 1702 (CvO);
1H NMR δ 7.35–7.25 (5H, br m), 5.25 (1H, m), 4.70 (1H, td, J =
6.5, 4.4 Hz), 4.07 (1H, dt, J = 7.5, 4 Hz), 3.87 (1H, apparent
quintuplet, J ∼ 6.2 Hz), 3.31 (3H, s), 3.29 (3H, overlapped m),
3.06 (1H, dd, J = 13, 10.7 Hz), 2.85 (1H, d, J = 11.3 Hz), 1.94
(1H, apparent heptuplet, J ∼ 6 Hz), 1.85 (1H, ddd, J = 14, 7.3,
4 Hz), 1.80–1.65 (2H, br m), 1.65–1.45 (4H, br m), 1.40–1.25 (6H,
br m), 1.00 (3H, t, J = 7.5 Hz), 0.90, 0.88 (21H, 2 × s, overlap-
ping one methyl triplet), 0.11 (6H, s), 0.10 (3H, s), 0.07 (3H, s);
13C NMR δ 201.1, 175.8, 136.8, 18.1, 18.0 (C), 129.5 (×2), 128.9
(×2), 127.2, 77.7, 70.9, 69.5, 67.6, 51.1 (CH), 43.8, 43.0, 36.5,
33.3, 32.1, 31.8, 24.5, 22.7, 21.8 (CH2), 56.1, 26.0 (×3), 25.9 (×3),
14.1, 11.6, −3.6 (×2), −4.1, −4.3 (CH3); HR ESMS m/z 732.3955
(M + Na+), calcd for C37H67NNaO4S2Si2, 732.3948.
(2S,3R,5S,7R)-3,5-Bis(tert-butyldimethylsilyloxy)-7-methoxy-
2-methyldodecanal (53). Oil: [α]D +13.8 (c 1.2; CHCl3); IR νmax
(cm−1): 1732 (CvO); 1H NMR δ 9.75 (1H, br s), 4.26 (1H, td, J =
6.3, 2.5 Hz), 3.83 (1H, m), 3.30 (3H, s), 3.29 (1H, m, overlapped
by the 3H singlet), 2.45 (1H, qd, J = 6.8, 2.5 Hz), 1.75 (1H, m),
1.65–1.55 (2H, m), 1.55–1.50 (2H, m), 1.45–1.40 (1H, m),
1.35–1.20 (6H, br m), 1.08 (3H, d, J = 6.8 Hz), 0.90 (12H, br s,
overlapping a methyl triplet), 0.86 (9H, s), 0.10 (6H, s), 0.09
(3H, s), 0.05 (3H, s); 13C NMR δ 18.1, 18.0 (C), 204.8, 77.5, 69.4,
67.4, 51.2 (CH), 43.3, 42.8, 33.1, 32.1, 24.5, 22.7 (CH2), 56.0,
25.9 (×3), 25.8 (×3), 14.1, 7.2, −3.8, −4.0, −4.1, −4.6 (CH3); HR
ESMS m/z 511.3621 (M + Na+), calcd for C26H56NaO4Si2,
511.3615.
(2S,3R,5S,7R)-3,5-Bis(tert-butyldimethylsilyloxy)-2-ethyl-7-
methoxydodecanal (54). Oil: [α]D +26.3 (c 1.3; CHCl3); IR νmax
(cm−1): 1727 (CvO); 1H NMR δ 9.80 (1H, d, J = 1.5 Hz), 4.18
(1H, m), 3.84 (1H, apparent quintuplet, J ∼ 6 Hz), 3.29 (3H, s),
3.24 (1H, m), 2.30 (1H, m), 1.80 (1H, m), 1.70 (1H, m),
1.65–1.60 (2H, m), 1.55–1.35 (4H, br m), 1.35–1.20 (6H, br m),
0.96 (3H, t, J = 7.5 Hz), 0.90, 0.88 (21H, 2 × s, overlapping one
methyl triplet), 0.11 (3H, s), 0.09 (6H, s), 0.08 (3H, s); 13C NMR
δ 18.1, 18.0 (C), 205.2, 77.6, 69.8, 67.6, 59.1 (CH), 43.1, 42.8,
33.2, 32.1, 24.5, 22.7, 17.2 (CH2), 56.1, 26.0 (×3), 25.8 (×3), 14.1,
12.4, −3.8, −3.9, −4.2, −4.4 (CH3); HR ESMS m/z 503.3956 (M +
H+), calcd for C27H59O4Si2, 503.3952.
Methyl (Z + E)-(4R,5R,7S,9R)-5,7-bis(tert-butyldimethylsilyl-
oxy)-9-methoxy-4-methyltetradec-2-enoate (55). A solution of
phosphonate (CF3CH2O)2POCH2COOMe (423 μL, 2 mmol) and
18-crown-6 (1.58 g, 6 mmol) in dry THF (10 mL) was cooled to
−40 °C and treated dropwise under N2 with KHMDS (commer-
cial 0.5 M solution in toluene, 4 mL, 2 mmol). The mixture
was then stirred for 1 h at the same temperature. After this, a
solution of aldehyde 53 (489 mg, 1 mmol) in dry THF (8 mL)
was added dropwise. The mixture was stirred for 3.5 h at
−40 °C. Standard work-up (EtOAc) aﬀorded enoate 55 as a
∼77 : 23 mixture of Z/E diastereoisomers. A careful column
chromatography on silica gel (hexanes–EtOAc, 49 : 1) permitted
the separation of both compounds and furnished (Z)-55
(379 mg, 70%) and (E)-55 (117 mg, 21%):
(Z)-55: oil, [α]D −31.8 (c 1.75; CHCl3); IR νmax (cm−1): 1723
(CvO); 1H NMR δ 6.21 (1H, dd, J = 11.5, 10 Hz), 5.77 (1H, br d,
J ∼ 11.5 Hz), 3.88 (1H, m), 3.74 (1H, m), 3.69 (3H, s), 3.57 (1H,
m), 3.32 (1H, m, overlapped by the OMe singlet), 3.30 (3H, s),
1.80–1.65 (2H, m), 1.60–1.40 (4H, br m), 1.35–1.20 (6H, br m),
1.00 (3H, d, J = 6.8 Hz), 0.89, 0.87 (21H, 2 × s, overlapping a
methyl triplet), 0.09 (3H, s), 0.08 (3H, s), 0.06 (3H, s), 0.02 (3H,
s); 13C NMR δ 166.5, 18.1, 18.0 (C), 153.4, 118.4, 77.5, 72.6, 67.5,
37.7 (CH), 43.8, 42.7, 33.5, 32.1, 24.6, 22.7 (CH2), 55.8, 51.0, 25.9
(×3), 25.8 (×3), 14.1, 14.0, −3.8, −4.0 (×2), −4.4 (CH3); HR ESMS
m/z 567.3871 (M + Na+), calcd for C29H60NaO5Si2, 567.3877.
(E)-55: oil, [α]D +31.4 (c 0.6; CHCl3); IR νmax (cm
−1): 1729
(CvO); 1H NMR δ 7.05 (1H, dd, J = 16, 6.6 Hz), 5.81 (1H, dd,
J ∼ 16, 1.5 Hz), 3.90–3.80 (2H, m), 3.72 (3H, s), 3.28 (3H, s), 3.26
(1H, m), 2.46 (1H, m), 1.65–1.55 (2H, m), 1.55–1.40 (4H, br m),
1.35–1.20 (6H, br m), 1.03 (3H, d, J = 6.8 Hz), 0.89 (21H, s, over-
lapping a methyl triplet), 0.09 (3H, s), 0.08 (3H, s), 0.07 (3H, s),
0.04 (3H, s); 13C NMR δ 167.1, 18.1 (×2) (C), 152.2, 120.5, 77.5,
72.7, 67.9, 41.7 (CH), 43.0, 42.9, 33.2, 32.1, 24.5, 22.7 (CH2),
56.0, 51.3, 25.9 (×6), 14.1, 13.0, −3.7, −3.8, −4.3 (×2) (CH3); HR
ESMS m/z 567.3880 (M + Na+), calcd for C29H60NaO5Si2,
567.3877.
Methyl (4R,5R,7S,9R,Z)-5,7-bis(tert-butyldimethylsilyloxy)-4-
ethyl-9-methoxytetradec-2-enoate (56). Obtained in 75% yield
and >95 : 5 Z/E stereoselectivity by means of olefination of
aldehyde 54 under the same conditions used for the prepa-
ration of 55: oil, [α]D −65.2 (c 1.1; CHCl3); IR νmax (cm−1): 1729
(CvO); 1H NMR δ 6.13 (1H, t, J = 11.3 Hz), 5.85 (1H, br d, J ∼
11.3 Hz), 3.90 (1H, m), 3.80 (1H, m), 3.70 (3H, s), 3.49 (1H, m),
3.31 (3H, s), 3.30 (1H, m, overlapped by the OMe singlet),
1.80–1.65 (2H, m), 1.65–1.55 (2H, m), 1.55–1.40 (4H, br m),
1.35–1.20 (6H, br m), 0.90, 0.88 (24H, 2 × s, overlapping two
methyl triplets), 0.10 (6H, s), 0.08 (3H, s), 0.04 (3H, s); 13C
NMR δ 166.6, 18.1 (×2) (C), 152.2, 120.2, 77.5, 72.3, 67.6, 45.0
(CH), 43.7, 42.8, 33.5, 32.1, 24.6, 22.7, 22.2 (CH2), 55.8, 51.0,
25.9 (×6), 14.1, 11.8, −3.8, −3.9 (×2), −4.3 (CH3); HR ESMS m/z
581.4032 (M + Na+), calcd for C30H62NaO5Si2, 581.4033.
Methyl (4R,5R,7R,9R,Z)-5,7-dihydroxy-9-methoxy-4-methyl-
tetradec-2-enoate (Z-57). Oil, [α]D −42.2 (c 1.2; CHCl3); IR νmax
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(cm−1): 3420 (br, OH), 1723 (CvO); 1H NMR δ 6.10 (1H, dd, J =
11.7, 10.3 Hz), 5.77 (1H, br d, J ∼ 11.7 Hz), 4.26 (1H, m), 3.87
(1H, m), 3.72 (3H, s), 3.62 (1H, m), 3.50 (1H, br s, OH), 3.47
(1H, m), 3.36 (3H, s), 3.20 (1H, br s, OH), 1.84 (1H, ddd, J =
14.5, 9.8, 3.8 Hz), 1.70–1.55 (5H, br m), 1.55–1.40 (2H, br m),
1.10 (3H, d, J = 6.8 Hz), 0.90 (3H, t, J = 6.8 Hz); 13C NMR δ
167.1 (C), 152.3, 119.4, 79.9, 72.7, 66.6, 38.7 (CH), 40.0, 38.8,
32.8, 32.0, 25.3, 22.6 (CH2), 56.8, 51.2, 16.0, 14.0 (CH3); HR
ESMS m/z 339.2150 (M + Na+), calcd for C17H32NaO5, 339.2147.
Methyl (4R,5R,7R,9R,E)-5,7-dihydroxy-9-methoxy-4-methyl-
tetradec-2-enoate (E-57). Oil, [α]D +39.8 (c 0.1; CHCl3); IR νmax
(cm−1): 3430 (br, OH), 1727 (CvO); 1H NMR δ 6.93 (1H, dd, J =
15.8, 8.3 Hz), 5.86 (1H, dd, J = 15.8, 1.5 Hz), 4.26 (1H, m), 3.87
(1H, m), 3.73 (3H, s), 3.60 (1H, br s, OH), 3.46 (1H, m), 3.36
(3H, s), 3.00 (1H, br s, OH), 2.47 (1H, m), 1.88 (1H, ddd, J =
14.5, 9.5, 3.8 Hz), 1.70–1.65 (1H, m), 1.60–1.40 (5H, br m),
1.35–1.20 (5H, br m), 1.13 (3H, d, J = 6.8 Hz), 0.89 (3H, t, J = 7
Hz); 13C NMR δ 167.0 (C), 151.3, 121.2, 80.1, 71.7, 66.6, 38.0
(CH), 42.9, 40.1, 32.5, 32.0, 25.3, 22.6 (CH2), 56.8, 51.5, 15.1,
14.0 (CH3); HR ESMS m/z 339.2142 (M + Na
+), calcd for
C17H32NaO5, 339.2147.
Methyl (4R,5R,7R,9R,Z)-4-ethyl-5,7-dihydroxy-9-methoxy-tetra-
dec-2-enoate (58). Oil, [α]D −33 (c 1.15; CHCl3); IR νmax
(cm−1): 3420 (br, OH), 1722 (CvO); 1H NMR δ 6.00 (1H, dd, J =
11.7, 9.8 Hz), 5.95 (1H, br d, J ∼ 11.7 Hz), 4.26 (1H, m), 3.94
(1H, m), 3.73 (3H, s), 3.55–3.40 (3H, br m, overlapping one OH
signal), 3.36 (4H, s, overlapping one OH signal), 1.85–1.75
(2H, m), 1.70–1.45 (8H, br m), 1.40–1.20 (8H, br m), 0.89 (6H,
two overlapped triplets); 13C NMR δ 167.4 (C), 151.2, 121.4,
79.9, 72.0, 66.6, 46.0 (CH), 39.7, 38.9, 32.8, 32.0, 25.3, 24.0,
22.6 (CH2), 56.8, 51.3, 14.0, 11.8 (CH3); HR ESMS m/z 353.2302
(M + Na+), calcd for C18H34NaO5, 353.2304.
Biological procedures
Cell culture
Human A549 non-small lung carcinoma cells were continu-
ously maintained in RPMI-1640 supplemented with 10% fetal
calf serum, 2 mM L-glutamine, 40 μg mL−1 gentamycin, 100 IU
mL−1 penicillin and 100 μg mL−1 streptomycin.19b Human
ovarian carcinoma A2780 (parental cell line) and A2780AD
(multidrug resistant cell line overexpressing P-glycoproteins)
were cultured as above with the addition of 0.25 unit per mL
of bovine insulin.
Cytotoxicity assays
A2780 and A2780AD cells were seeded in 96 well plates at a
density of 15 000 cells in 0.08 mL per well. On the following
day, the cells were exposed to 0.02 mL serial dilutions of
ligands for 48 hours, after which time a modified MTT assay40
was performed in order to determine viable cells. For this
purpose, 20 μL of 2.5 mg mL−1 of 3-(4,5-dimethylthiazol-2-yl)-
2,5-diphenyltetrazolium bromide (MTT) was added to each
well, incubated for 4 h at 37 °C, and then treated with 0.1 mL
MTT solubilizer (10% SDS, 45% dimethylformamide, pH 5.5).
Plates were again incubated overnight at 37 °C in order to solu-
bilize the blue formazan precipitate before measuring the
absorbance at 595/690 nm in an automated Multiscan micro-
plate reader. Control wells containing medium without cells
were used as blanks. MTT response is expressed as a percen-
tage of the control (untreated) cells. The IC50 was calculated
from the log–dose response curves.
Indirect immunofluorescence
A549 cells were plated at a density of 150 000 cells per mL onto
24 well tissue culture plates containing 12 mm round cover-
slips, cultured overnight and then treated with ligands at
diﬀerent concentrations or with drug vehicle (DMSO) for
24 hours. Residual DMSO was less than 0.5%. Attached cells
were permeabilized with Triton X-100 and fixed with 3.7% for-
maldehyde, as previously described.41 Cytoskeletons were incu-
bated with DM1A monoclonal antibody reacting with
α-tubulin, washed twice and incubated with FITC goat anti-
mouse immunoglobulins. The coverslips were washed with
1 μg mL−1 Hoechst 33342 in order to stain the chromatin.
After washing, the samples were examined and photographed
using a Zeiss Axioplan epifluorescence microscope. The
images were recorded with a Hamamatsu 4742-95 cooled CCD
camera.
Cell cycle analysis
Progression through the cell cycle was assessed by flow cyto-
metry DNA determination with propidium iodide. Cells
(150 000 per mL) were incubated with several concentrations of
the drugs for 24 hours. The cells were fixed with 70% ethanol,
treated with RNase and stained with propidium iodide as pre-
viously described.42 The analysis was performed with a Coulter
Epics XL flow cytometer.
Eﬀects of ligands on microtubule assembly
The eﬀect of the pironetin analogues in the assembly of puri-
fied tubulin was determined by incubating 20 μM of purified
tubulin at 37 °C for 30 minutes in GAB (glycerol assembling
buﬀer, 3.4 M glycerol, 10 mM sodium phosphate, 1 mM EGTA,
1 mM GTP, 6 mM MgCl2 at pH 6.5) in the presence of 25 μM
docetaxel, 100 μM of an appropriate analogue or 2 μL DMSO
(vehicle). In this buﬀer, tubulin can assemble without ligand
with a critical concentration of about 3.3 μM.43 The polymers
were sedimented at 90 000g for 20 minutes in a TLA 100 rotor,
preequilibrated at 37 °C, in a Beckman Optima TLX ultracen-
trifuge. The supernatants were carefully removed by pipetting,
and the pellets were resuspended in 10 mM phosphate, 1%
SDS, pH 7.0. The pellets and the supernatants were diluted
1 : 10 in the same buﬀer, and their concentrations were fluori-
metrically measured employing a Fluorolog 3 spectrofluori-
meter (excitation wavelength 285 nm, emission wavelength
320 nm using slits of 2 and 5 nm, respectively). Tubulin con-
centration standard curves were constructed for each exper-
iment, using spectrophotometrically measured concentrations
of purified tubulin. The critical concentration for tubulin
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assembly37 in the presence of the ligands was calculated as
described.42
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